{"text": "In a separate study , a gastric NE - cell tumor without concomitant ECL - cell proliferative changes was observed in 1 female rat following 12 months of dosing with pantoprazole at 5 mg / kg / day and a 9 month off - dose recovery [ see Nonclinical Toxicology ( 13.1 ) ] .", "label": "", "metadata": {}, "score": "31.13121"}
{"text": "In a separate study , a gastric NE - cell tumor without concomitant ECL - cell proliferative changes was observed in 1 female rat following 12 months of dosing with pantoprazole at 5 mg / kg / day and a 9 month off - dose recovery [ see Nonclinical Toxicology ( 13.1 ) ] .", "label": "", "metadata": {}, "score": "31.13121"}
{"text": "In a separate study , a gastric NE - cell tumor without concomitant ECL - cell proliferative changes was observed in 1 female rat following 12 months of dosing with pantoprazole at 5 mg / kg / day and a 9 month off - dose recovery [ see Nonclinical Toxicology ( 13.1 ) ] .", "label": "", "metadata": {}, "score": "31.13121"}
{"text": "A significantly greater proportion of patients taking pantoprazole sodium 40 mg experienced complete relief of daytime and nighttime heartburn and the absence of regurgitation , starting from the first day of treatment , compared with placebo .", "label": "", "metadata": {}, "score": "31.987226"}
{"text": "In case of overdose , treatment should be symptomatic and supportive .Single intravenous doses of pantoprazole at 378 , 230 , and 266 mg / kg ( 38 , 46 , and 177 times the recommended human dose based on body surface area ) were lethal to mice , rats and dogs , respectively .", "label": "", "metadata": {}, "score": "33.166656"}
{"text": "At the start of the study , the six patients treated with cinacalcet showed a more severe picture of biochemical abnormalities when compared with the control patients .", "label": "", "metadata": {}, "score": "33.475986"}
{"text": "After a single oral dose of 14 C - labeled pantoprazole to healthy , normal metabolizer volunteers , approximately 71 % of the dose was excreted in the urine , with 18 % excreted in the feces through biliary excretion .", "label": "", "metadata": {}, "score": "33.805275"}
{"text": "After the initial 5 days , all patients were treated with 40 mg oral pantoprazole daily to complete a total of 8 weeks of treatment .", "label": "", "metadata": {}, "score": "33.847244"}
{"text": "In a 5-day study of oral pantoprazole with 40 and 60 mg doses in healthy subjects , following the last dose on day 5 , median 24-hour serum gastrin concentrations were elevated by 3 - 4 fold compared to placebo in both 40 and 60 mg dose groups .", "label": "", "metadata": {}, "score": "34.00963"}
{"text": "In a nonclinical study in Sprague - Dawley rats , lifetime exposure ( 24 months ) to pantoprazole at doses of 0.5 to 200 mg / kg / day resulted in dose - related increases in gastric ECL cell proliferation and gastric neuroendocrine ( NE)-cell tumors .", "label": "", "metadata": {}, "score": "34.32129"}
{"text": "Under maximal acid stimulatory conditions using pentagastrin , a dose - dependent decrease in gastric acid output occurs after a single dose of oral ( 20 - 80 mg ) pantoprazole in healthy volunteers .", "label": "", "metadata": {}, "score": "34.334145"}
{"text": "Dose selection for this study may not have been adequate to comprehensively evaluate the carcinogenic potential of pantoprazole .In a 24-month carcinogenicity study , B6C3F1 mice were treated orally with doses of 5 to 150 mg / kg / day , 0.5 to 15 times the recommended human dose based on body surface area .", "label": "", "metadata": {}, "score": "34.890587"}
{"text": "Dose selection for this study may not have been adequate to comprehensively evaluate the carcinogenic potential of pantoprazole .In a 24-month carcinogenicity study , B6C3F1 mice were treated orally with doses of 5 to 150 mg / kg / day , 0.5 to 15 times the recommended human dose based on body surface area .", "label": "", "metadata": {}, "score": "34.890587"}
{"text": "In case of overdosage , treatment should be symptomatic and supportive .Single oral doses of pantoprazole at 709 mg / kg , 798 mg / kg , and 887 mg / kg were lethal to mice , rats , and dogs , respectively .", "label": "", "metadata": {}, "score": "35.55562"}
{"text": "Participants were given matching placebo tablets compared to the cinacalcet group .[ 3 ] .Participants who completed study includes those with ended study due to death .", "label": "", "metadata": {}, "score": "35.610573"}
{"text": "Two independent , multicenter , randomized , double - blind , comparator - controlled trials of identical design were conducted in adult GERD patients with endoscopically confirmed healed erosive esophagitis to demonstrate efficacy of pantoprazole sodium in long - term maintenance of healing .", "label": "", "metadata": {}, "score": "35.68779"}
{"text": "Two independent , multicenter , randomized , double - blind , comparator - controlled trials of identical design were conducted in adult GERD patients with endoscopically confirmed healed erosive esophagitis to demonstrate efficacy of Pantoprazole in long - term maintenance of healing .", "label": "", "metadata": {}, "score": "35.72843"}
{"text": "In this study , all pantoprazole sodium treatment groups had significantly greater healing rates than the placebo group .This was true regardless of H. pylori status for the 40 mg and 20 mg pantoprazole sodium treatment groups .", "label": "", "metadata": {}, "score": "36.13325"}
{"text": "The incidence rates of adverse reactions were also similar for men and women . 8.7 Patients with Hepatic Impairment .10 OVERDOSAGE .Spontaneous post - marketing reports of overdose are generally within the known safety profile of Pantoprazole .", "label": "", "metadata": {}, "score": "36.73226"}
{"text": "In a 1-year study of GERD patients treated with Pantoprazole 40 mg or 20 mg , there were no changes from baseline in overall levels of T 3 , T 4 , and TSH .", "label": "", "metadata": {}, "score": "36.779488"}
{"text": "In addition , Block et al . reported its benefit of cardiovascular protection in a large observational study for hemodialysis subjects [ 16 ] .More recently , considerable evidences also exhibited that combination administration of a low dose of vitamin D and stepped - up cinacalcet provide apparent efficacy in treating UHPT [ 17 , 18 , 19 ] .", "label": "", "metadata": {}, "score": "36.930733"}
{"text": "In most patients , treatment of hypomagnesemia required magnesium replacement and discontinuation of the PPI .5.6 Tumorigenicity .Due to the chronic nature of GERD , there may be a potential for prolonged administration of Pantoprazole .", "label": "", "metadata": {}, "score": "36.94189"}
{"text": "There is no evidence that any of the pantoprazole metabolites have significant pharmacologic activity .Elimination .After a single oral or intravenous dose of 14 C - labeled pantoprazole to healthy , normal metabolizer volunteers , approximately 71 % of the dose was excreted in the urine , with 18 % excreted in the feces through biliary excretion .", "label": "", "metadata": {}, "score": "37.12624"}
{"text": "After 6 months of treatment , a statistically significant reduction in the serum levels of iPTH , Ca , P and CaxP product was obtained only in the patients treated with cinacalcet .", "label": "", "metadata": {}, "score": "37.476555"}
{"text": "Single oral doses of pantoprazole at 709 mg / kg , 798 mg / kg , and 887 mg / kg were lethal to mice , rats , and dogs , respectively .", "label": "", "metadata": {}, "score": "37.781548"}
{"text": "Our study also showed similar benefits of combined therapy .Meanwhile , a lower dose of cinacalcet , which is sufficiently effective to suppress iPTH levels , has been observed in Japanese patients [ 27 ] .", "label": "", "metadata": {}, "score": "37.821537"}
{"text": "A similar increase in serum gastrin levels was noted at the 8-week visit with mean increases of 3 % , 26 % , and 84 % for the three pantoprazole dose groups .", "label": "", "metadata": {}, "score": "38.078865"}
{"text": "A similar increase in serum gastrin levels was noted at the 8-week visit with mean increases of 3 % , 26 % , and 84 % for the three pantoprazole dose groups .", "label": "", "metadata": {}, "score": "38.078865"}
{"text": "In a multicenter , open - label trial of 35 patients with pathological hypersecretory conditions , such as Zollinger - Ellison syndrome , with or without multiple endocrine neoplasia - type I , pantoprazole sodium successfully controlled gastric acid secretion .", "label": "", "metadata": {}, "score": "38.29548"}
{"text": "Antisecretory Activity .Under maximal acid stimulatory conditions using pentagastrin , a dose - dependent decrease in gastric acid output occurs after a single dose of oral ( 20 to 80 mg ) or a single dose of intravenous ( 20 to 120 mg ) pantoprazole in healthy volunteers .", "label": "", "metadata": {}, "score": "38.55965"}
{"text": "Pantoprazole sodium 20 mg , administered once daily , was also effective in reducing episodes of daytime and nighttime heartburn in one trial , as presented in Table 8 .", "label": "", "metadata": {}, "score": "38.677578"}
{"text": "Patients were administered all test medication with a light meal .MAO was estimated from a 1 hour continuous collection of gastric contents following subcutaneous injection of 6.0 \u03bcg / kg of pentagastrin .", "label": "", "metadata": {}, "score": "38.71384"}
{"text": "In other in vivo studies , digoxin , ethanol , glyburide , antipyrine , caffeine , metronidazole , and amoxicillin had no clinically relevant interactions with pantoprazole .", "label": "", "metadata": {}, "score": "38.92292"}
{"text": "In the 122 women treated long - term with pantoprazole sodium 40 mg or 20 mg , healing was maintained at a rate similar to that in men .", "label": "", "metadata": {}, "score": "38.98137"}
{"text": "The clinical significance of this finding in a large population of subjects administered intravenous pantoprazole is unknown .[ see Adverse Reactions ( 6 ) ] .", "label": "", "metadata": {}, "score": "39.194595"}
{"text": "There was a 78 % reduction in the C max and a 45 % reduction in the AUC of MPA in patients receiving both pantoprazole and MMF .", "label": "", "metadata": {}, "score": "39.236076"}
{"text": "The 40 mg dose of Pantoprazole resulted in healing rates significantly greater than those found with either the 20 mg or 10 mg dose .A significantly greater proportion of patients taking Pantoprazole 40 mg experienced complete relief of daytime and nighttime heartburn and the absence of regurgitation , starting from the first day of treatment , compared with placebo .", "label": "", "metadata": {}, "score": "39.360954"}
{"text": "The incidence rates of adverse reactions were also similar for men and women . 8.7Hepatic Impairment .10 OVERDOSAGE .Adverse events seen in spontaneous reports of overdose generally reflect the known safety profile of pantoprazole .", "label": "", "metadata": {}, "score": "39.417835"}
{"text": "There are no data available on the effects of intravenous pantoprazole on ECL cells .In a nonclinical study in Sprague - Dawley rats , lifetime exposure ( 24 months ) to pantoprazole at doses of 0.5 to 200 mg / kg / day resulted in dose - related increases in gastric ECL - cell proliferation and gastric neuroendocrine ( NE)-cell tumors .", "label": "", "metadata": {}, "score": "39.444946"}
{"text": "Other Effects .In a 1-year study of GERD patients treated with pantoprazole sodium 40 mg or 20 mg , there were no changes from baseline in overall levels of T 3 , T 4 , and TSH .", "label": "", "metadata": {}, "score": "39.55035"}
{"text": "Cinacalcet administered orally in doses of 30 , 60 , 90 , 120 or 180 mg per day .Participants could be titrated up to maximum dose based on PTH ( parathyroid hormone ) , serum calcium and safety assessments .", "label": "", "metadata": {}, "score": "39.586025"}
{"text": "Pantoprazole 40 mg was superior to ranitidine in reducing the number of daytime and nighttime heartburn episodes from the first through the twelfth month of treatment .", "label": "", "metadata": {}, "score": "39.872772"}
{"text": "Drug - Drug Interactions .Pantoprazole is metabolized mainly by CYP2C19 and to minor extents by CYPs 3A4 , 2D6 , and 2C9 .Clopidogrel is metabolized to its active metabolite in part by CYP2C19 .", "label": "", "metadata": {}, "score": "40.541946"}
{"text": "Discussion The efficacy of cinacalcet compared with placebo in decreasing PTH concentrations in haemodialysis patients with SHPTH was shown in several published studies [ 10 - 13 ] , thus increasing the percentage of subjects who are able to achieve the NKF / K - DOQI targets [ 7,9].", "label": "", "metadata": {}, "score": "40.754845"}
{"text": "The relevance of these findings to tumor development in humans is unknown [ see Nonclinical Toxicology ( 13.1 ) ] .5.7 Interference with Urine Screen for THC . 5.8 Concomitant use of Pantoprazole with Methotrexate .", "label": "", "metadata": {}, "score": "40.992874"}
{"text": "Pantoprazole 40 mg and 20 mg once daily were also compared with nizatidine 150 mg twice daily in a US multicenter , double - blind study of 243 patients with reflux symptoms and endoscopically diagnosed EE of grade 2 or above .", "label": "", "metadata": {}, "score": "41.11795"}
{"text": "In this study , approximately 25 % of enrolled patients had severe EE of grade 3 , and 10 % had grade 4 .In this study , all Pantoprazole treatment groups had significantly greater healing rates than the placebo group .", "label": "", "metadata": {}, "score": "41.352074"}
{"text": "The clinical significance of this finding is not clear .Dosage adjustment of these drugs is not necessary when they are coadministered with pantoprazole .In other in vivo studies , digoxin , ethanol , glyburide , antipyrine , caffeine , metronidazole , and amoxicillin had no clinically relevant interactions with pantoprazole .", "label": "", "metadata": {}, "score": "42.704857"}
{"text": "7.3 Clopidogrel .Concomitant administration of pantoprazole and clopidogrel in healthy subjects had no clinically important effect on exposure to the active metabolite of clopidogrel or clopidogrel - induced platelet inhibition [ see Clinical Pharmacology ( 12.3 ) ] .", "label": "", "metadata": {}, "score": "42.714615"}
{"text": "7.3 Clopidogrel .Concomitant administration of pantoprazole and clopidogrel in healthy subjects had no clinically important effect on exposure to the active metabolite of clopidogrel or clopidogrel - induced platelet inhibition [ see Clinical Pharmacology ( 12.3 ) ] .", "label": "", "metadata": {}, "score": "42.714615"}
{"text": "Moreover , efficacy of cinacalcet may be limited in some patients by its gastrointestinal adverse effects , which may be more frequent in real - world patients compared to selected patients enrolled in a randomized - controlled trial .", "label": "", "metadata": {}, "score": "42.71759"}
{"text": "These episodes were treated imme- diately with infusions of Ca gluconate and thereafter by increasing the oral doses of Ca carbonate and/or by adding oral calcitriol to the treatment .", "label": "", "metadata": {}, "score": "42.787354"}
{"text": "Pantoprazole sodium 40 mg and 20 mg once daily were also compared with nizatidine 150 mg twice daily in a US multicenter , double - blind study of 243 patients with reflux symptoms and endoscopically diagnosed EE of grade 2 or above .", "label": "", "metadata": {}, "score": "42.8255"}
{"text": "[See Adverse Reactions 6.2 ) ] .Due to the chronic nature of GERD , there may be a potential for prolonged administration of pantoprazole sodium .", "label": "", "metadata": {}, "score": "42.95938"}
{"text": "Pantoprazole Sodium Delayed - Release Tablets should be swallowed whole , with or without food in the stomach .If patients are unable to swallow a 40 mg tablet , two 20 mg tablets may be taken .", "label": "", "metadata": {}, "score": "42.96238"}
{"text": "The aim of this single - centre prospective study was to evaluate the therapeutic efficacy of cinacalcet in this high - risk category of patients .", "label": "", "metadata": {}, "score": "43.05206"}
{"text": "Description .Placebo .No text entered .Cinacalcet .Cinacalcet administered orally in doses of 30 , 60 , 90 , 120 or 180 mg per day .", "label": "", "metadata": {}, "score": "43.103416"}
{"text": "Healthy subjects received a continuous infusion for 25 hours of pentagastrin ( PG ) at 1 mcg / kg / h , a dose known to produce submaximal gastric acid secretion .", "label": "", "metadata": {}, "score": "43.18409"}
{"text": "On the contrary , the proportion of patients using sevelamer increased until 2005 then remained fairly stable .The average daily dose of sevelamer followed the same pattern of use .", "label": "", "metadata": {}, "score": "43.196568"}
{"text": "In patients with mild to severe hepatic impairment ( Child - Pugh A to C cirrhosis ) , maximum pantoprazole concentrations increased only slightly ( 1.5-fold ) relative to healthy subjects .", "label": "", "metadata": {}, "score": "43.23179"}
{"text": "Concomitant administration of antacids does not affect the absorption of pantoprazole sodium delayed - release tablets USP .4 CONTRAINDICATIONS .Pantoprazole sodium delayed - release tablets USP are contraindicated in patients with known hypersensitivity to any component of the formulation [ see Description ( 11 ) ] or any substituted benzimidazole .", "label": "", "metadata": {}, "score": "43.449356"}
{"text": "Clopidogrel : Clopidogrel is metabolized to its active metabolite in part by CYP2C19 .In a crossover clinical study , 66 healthy subjects were administered clopidogrel ( 300 mg loading dose followed by 75 mg per day ) alone and with pantoprazole ( 80 mg at the same time as clopidogrel ) for 5 days .", "label": "", "metadata": {}, "score": "43.567986"}
{"text": "The magnitude and time course for inhibition of pentagastrin - stimulated acid output ( PSAO ) by single doses ( 20 to 120 mg ) of PROTONIX I.V. for Injection were assessed in a single - dose , open - label , placebo - controlled , dose - response study .", "label": "", "metadata": {}, "score": "43.603756"}
{"text": "In patients with severe renal impairment , pharmacokinetic parameters for pantoprazole were similar to those of healthy subjects .No dosage adjustment is necessary in patients with renal impairment or in patients undergoing hemodialysis .", "label": "", "metadata": {}, "score": "43.743607"}
{"text": "In patients with severe renal impairment , pharmacokinetic parameters for pantoprazole were similar to those of healthy subjects .No dosage adjustment is necessary in patients with renal impairment or in patients undergoing hemodialysis .", "label": "", "metadata": {}, "score": "43.743607"}
{"text": "No dosage adjustment is necessary in patients with renal impairment or in patients undergoing hemodialysis .In patients with mild to severe hepatic impairment ( Child - Pugh A to C cirrhosis ) , maximum pantoprazole concentrations increased only slightly ( 1.5-fold ) relative to healthy subjects .", "label": "", "metadata": {}, "score": "43.896935"}
{"text": "Our single - centre prospective study , even though small and of short duration , shows that cinacalcet is effective also in controlling relapses of SHPTH after PTx , thus representing a solid , and sometimes unique , therapeutic opportunity for this high - risk category of patients .", "label": "", "metadata": {}, "score": "44.01374"}
{"text": "Our single - centre prospective study , even though small and of short duration , shows that cinacalcet is effective also in controlling relapses of SHPTH after PTx , thus representing a solid , and sometimes unique , therapeutic opportunity for this high - risk category of patients .", "label": "", "metadata": {}, "score": "44.01374"}
{"text": "CONTRAINDICATIONS .Known hypersensitivity to any component of the formulation or to substituted benzimidazoles ( 4 ) .WARNINGS AND PRECAUTIONS .Symptomatic response to therapy with pantoprazole does not preclude the presence of gastric malignancy ( 5.1 ) .", "label": "", "metadata": {}, "score": "44.15561"}
{"text": "In high - dose methotrexate administration , a temporary withdrawal of the PPI may be considered in some patients [ see Drug Interactions ( 7.6 ) ] . 6", "label": "", "metadata": {}, "score": "44.53322"}
{"text": "In high - dose methotrexate administration , a temporary withdrawal of the PPI may be considered in some patients [ see Drug Interactions ( 7.6 ) ] . 6", "label": "", "metadata": {}, "score": "44.53322"}
{"text": "The aim of this single - centre prospective study was to evaluate the therapeutic efficacy of cinacalcet in the metabolic control of relapses of SHPTH after PTx .", "label": "", "metadata": {}, "score": "44.594433"}
{"text": "The most frequently occurring adverse reactions are listed in Table 1 .The number of patients treated in comparative studies with I.V. pantoprazole is limited ; however , the adverse reactions seen were similar to those seen in the oral studies .", "label": "", "metadata": {}, "score": "44.651787"}
{"text": "In order to ensure prescriptions were being fulfilled , two dispensations were requested for each patient .The average daily dose for selected medication was calculated including : calcium - containing binders , sevelamer , lanthanum , alfacalcidol , calcitriol , and cinacalcet .", "label": "", "metadata": {}, "score": "44.68561"}
{"text": "As demonstrated in Table 7 , Pantoprazole 40 mg and 20 mg were significantly superior to ranitidine at every timepoint with respect to the maintenance of healing .", "label": "", "metadata": {}, "score": "45.00748"}
{"text": "Combination Therapy of Low - Dose Cinacalcet and Calcitriol to Reduce Hypocalcemia Episodes and Use of Aluminum Hydroxide .The most reported side effect of cinacalcet treatment is gastrointestinal disorders , including nausea , vomiting , and diarrhea [ 29 ] .", "label": "", "metadata": {}, "score": "45.086945"}
{"text": "These side effects advised us to be more prudent in increasing the doses of cinacalcet .These episodes indicate a greater difficulty in metabolic compensation in patients after PTx , whose causes remain to be elucidated .", "label": "", "metadata": {}, "score": "45.12435"}
{"text": "For the 40 mg treatment group , significantly greater healing rates compared to nizatidine were achieved regardless of the H. pylori status .A significantly greater proportion of the patients in the Pantoprazole treatment groups experienced complete relief of nighttime heartburn and regurgitation , starting on the first day and of daytime heartburn on the second day , compared with those taking nizatidine 150 mg twice daily .", "label": "", "metadata": {}, "score": "45.23849"}
{"text": "Pantoprazole Sodium Delayed - Release Tablets ( 40 mg and 20 mg ) complies with USP dissolution test 4 . 12 CLINICAL PHARMACOLOGY .12.1 Mechanism of Action .", "label": "", "metadata": {}, "score": "45.52632"}
{"text": "No dose adjustment of clopidogrel is necessary when administered with an approved dose of pantoprazole sodium .Pantoprazole causes long - lasting inhibition of gastric acid secretion .", "label": "", "metadata": {}, "score": "45.579678"}
{"text": "Table 3 ) , thus , well before the introduction of calcitriol in the treatment .Thus , we can conclude that our single - centre prospective study , even though small and of short duration , shows that cinacalcet represents a solid , and sometimes unique , therapeutic opportunity for patients affected by relapses of SHPTH after PTx .", "label": "", "metadata": {}, "score": "45.584167"}
{"text": "No gender - related differences in the safety profile of intravenous pantoprazole were seen in international trials involving 166 men and 120 women with erosive esophagitis associated with GERD .", "label": "", "metadata": {}, "score": "45.610424"}
{"text": "Following the initial oral dose of 40 mg pantoprazole , a 51 % mean inhibition was achieved by 2.5 hours .With once - a - day dosing for 7 days , the mean inhibition was increased to 85 % .", "label": "", "metadata": {}, "score": "45.820484"}
{"text": "Following the initial oral dose of 40 mg pantoprazole , a 51 % mean inhibition was achieved by 2.5 hours .With once - a - day dosing for 7 days , the mean inhibition was increased to 85 % .", "label": "", "metadata": {}, "score": "45.820484"}
{"text": "In another placebo - controlled , 7-day study of 40 mg intravenous or oral pantoprazole in patients with GERD and a history of erosive esophagitis , the mean serum gastrin concentration increased approximately 50 % from baseline and as compared with placebo , but remained within the normal range .", "label": "", "metadata": {}, "score": "45.828224"}
{"text": "For the 40 mg treatment group , significantly greater healing rates compared to nizatidine were achieved regardless of the H. pylori status .A significantly greater proportion of the patients in the pantoprazole sodium treatment groups experienced complete relief of nighttime heartburn and regurgitation , starting on the first day and of daytime heartburn on the second day , compared with those taking nizatidine 150 mg twice daily .", "label": "", "metadata": {}, "score": "46.289196"}
{"text": "According to Amgen internal data , 4 patients received cinacalcet through this program in 2004 , 40 in 2005 , and 58 in 2006 .Some private insurance companies may have reimbursed cinacalcet for patients not covered by the provincial RAMQ drug plan .", "label": "", "metadata": {}, "score": "46.46112"}
{"text": "In conclusion , our single - centre prospective study , even though small and of short duration , shows that cinacalcet is effective also in controlling relapses of SHPTH after PTx , thus representing a solid , and sometimes unique , therapeutic opportunity for this high - risk category of patients .", "label": "", "metadata": {}, "score": "46.490807"}
{"text": "The duration of action of PROTONIX I.V. for Injection was 24 hours .In one study of gastric pH in healthy subjects , pantoprazole was administered orally ( 40 mg enteric coated tablets ) or intravenously ( 40 mg ) once daily for 5 days and pH was measured for 24 hours following the fifth dose .", "label": "", "metadata": {}, "score": "47.023865"}
{"text": "We report the results of the efficacy of the calcimimetic cinacalcet in six hemodialysis ( HD ) and three peritoneal dialysis ( PD ) pediatric patients with HTBD , age 14.5 + /- 1.0 ( range 7.5 - 17.5 ) years .", "label": "", "metadata": {}, "score": "47.136333"}
{"text": "In a 24-month carcinogenicity study , B6C3F1 mice were treated orally with doses of 5 to 150 mg / kg / day , 0.5 to 15 times the recommended human dose based on body surface area .", "label": "", "metadata": {}, "score": "47.18345"}
{"text": "An alternative confirmatory method should be considered to verify positive results . 7.6 Methotrexate .Case reports , published population pharmacokinetic studies , and retrospective analyses suggest that concomitant administration of PPIs and methotrexate ( primarily at high dose ; see methotrexate prescribing information ) may elevate and prolong serum levels of methotrexate and/or its metabolite hydroxymethotrexate .", "label": "", "metadata": {}, "score": "47.29325"}
{"text": "Acid secretion had returned to normal within a week after the last dose of pantoprazole ; there was no evidence of rebound hypersecretion .Treatment with 40 mg of pantoprazole produced significantly greater increases in gastric pH than the 20 mg dose .", "label": "", "metadata": {}, "score": "47.30151"}
{"text": "Acid secretion had returned to normal within a week after the last dose of pantoprazole ; there was no evidence of rebound hypersecretion .Treatment with 40 mg of pantoprazole produced significantly greater increases in gastric pH than the 20 mg dose .", "label": "", "metadata": {}, "score": "47.30151"}
{"text": "Adult Patients .A US multicenter , double - blind , placebo - controlled study of pantoprazole sodium 10 mg , 20 mg , or 40 mg once daily was conducted in 603 patients with reflux symptoms and endoscopically diagnosed EE of grade 2 or above ( Hetzel - Dent scale ) .", "label": "", "metadata": {}, "score": "47.34855"}
{"text": "Table 4 : Effect of Single Daily Doses of Oral Pantoprazole on Intragastric pH .Fasting serum gastrin levels were assessed in two double - blind studies of the acute healing of erosive esophagitis ( EE ) in which 682 patients with gastroesophageal reflux disease ( GERD ) received 10 , 20 , or 40 mg of pantoprazole sodium for up to 8 weeks .", "label": "", "metadata": {}, "score": "47.399536"}
{"text": "These are not all the possible side effects with pantoprazole sodium delayed - release tablets .Talk with your doctor or pharmacist if you have any questions about side effects .", "label": "", "metadata": {}, "score": "47.4215"}
{"text": "At the start of the study , the six patients treated with cinacalcet showed a more severe picture of biochemicalabnormalities the control patients ( Table 2 ) : in fact , they had higher mean serum levels of iPTH ( 1388.3 ?", "label": "", "metadata": {}, "score": "47.457794"}
{"text": "Our results are consistent with a pooled analysis of short duration trials that showed a reduce incidence of PTX with cinacalcet ( from 41 /1000p - y in the placebo group to 3 /1000 p - y in the cinacalcet group ) [ 3 ] .", "label": "", "metadata": {}, "score": "47.577026"}
{"text": "Furthermore , although hypocalcemia is not uncommon during cinacalcet management , the present study identified that incidence of hypocalcemia was comparable between combined therapy and calcitriol alone .", "label": "", "metadata": {}, "score": "47.79585"}
{"text": "Intern .Med .[ Google Scholar ] .Goodman , W.G. ; Frazao , J.M. ; Goodkin , D.A. ; Turner , S.A. ; Liu , W. ; Coburn , J.W. A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism .", "label": "", "metadata": {}, "score": "48.609146"}
{"text": "In those patients who need a higher dosage , 80 mg intravenously every 8 hours is expected to maintain acid output below 10 mEq / h .", "label": "", "metadata": {}, "score": "48.611675"}
{"text": "The following adverse reactions have been identified during postapproval use of Pantoprazole .Because these reactions are reported voluntarily from a population of uncertain size , it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure .", "label": "", "metadata": {}, "score": "48.74182"}
{"text": "Change in rates may be due to other factors occurring simultaneously with the introduction of cinacalcet .For example , following the publication of the KDOQI Guidelines use of more aggressive treatments such as higher doses of phosphate binders and vitamin D may explain lower PTX rates with time [ 1 , 19 ] .", "label": "", "metadata": {}, "score": "48.75257"}
{"text": "Administration of pantoprazole sodium delayed - release tablets with food may delay its absorption up to 2 hours or longer ; however , the Cmax and the extent of pantoprazole absorption ( AUC ) are not altered .", "label": "", "metadata": {}, "score": "48.849327"}
{"text": "The aim was to limit hypocalcaemia induced by cinacalcet by maximizing the transfer of Ca ions from the dialysate to the blood , as recommended also by the NKF / K - DOQI guidelines [ 9].", "label": "", "metadata": {}, "score": "48.98146"}
{"text": "There will be up to two other overnight hospital stays ( 1 to 3 nights ) to adjust cinacalcet doses .The dose will increase until the maximum dose is reached , or side effects develop .", "label": "", "metadata": {}, "score": "49.439865"}
{"text": "ADP ) was correlated with the change in the exposure to clopidogrel active metabolite .The clinical significance of this finding is not clear .Dosage adjustment of these drugs is not necessary when they are coadministered with pantoprazole .", "label": "", "metadata": {}, "score": "49.644398"}
{"text": "11 DESCRIPTION .The active ingredient in pantoprazole sodium delayed - release tablets USP is a substituted benzimidazole , sodium 5-(difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridinyl)methyl ] sulfinyl]1H- benzimidazole sesquihydrate , a compound that inhibits gastric acid secretion .", "label": "", "metadata": {}, "score": "49.706505"}
{"text": "Patient Instructions for Use .Pantoprazole Sodium Delayed - Release Tablets .You can take pantoprazole sodium delayed - release tablets with food or on an empty stomach .", "label": "", "metadata": {}, "score": "49.717243"}
{"text": "As demonstrated in Table 7 , pantoprazole sodium 40 mg and 20 mg were significantly superior to ranitidine at every timepoint with respect to the maintenance of healing .", "label": "", "metadata": {}, "score": "49.7713"}
{"text": "See Warnings and Precautions ( 5.7 ) ] .Read the Patient Information that comes with pantoprazole sodium delayed - release tablets before you start taking it and each time you get a refill .", "label": "", "metadata": {}, "score": "49.777077"}
{"text": "The study found that diabetic patients who used calcium - based phosphate binders experienced more rapid and more severe progression of coronary artery calcification than those using sevelamer .", "label": "", "metadata": {}, "score": "49.78889"}
{"text": "Reporting Groups .Description .Cinacalcet .Cinacalcet administered orally in doses of 30 , 60 , 90 , 120 or 180 mg per day .", "label": "", "metadata": {}, "score": "49.839977"}
{"text": "Absorption .After administration of a single or multiple oral 40 mg doses of pantoprazole sodium delayed - release tablets , the peak plasma concentration of pantoprazole was achieved in approximately 2.5 hours , and Cmax was 2.5 mcg / mL. Pantoprazole undergoes little first - pass metabolism , resulting in an absolute bioavailability of approximately 77 % .", "label": "", "metadata": {}, "score": "49.846035"}
{"text": "Pantoprazole sodium delayed - release tablets USP are indicated in adults for the short - term treatment ( up to 8 weeks ) in the healing and symptomatic relief of erosive esophagitis .", "label": "", "metadata": {}, "score": "49.863274"}
{"text": "There was also no interaction with concomitantly administered antacids .There have been postmarketing reports of increased INR and prothrombin time in patients receiving proton pump inhibitors , including pantoprazole sodium , and warfarin concomitantly [ see Drug Interactions ( 7.2)].", "label": "", "metadata": {}, "score": "49.97504"}
{"text": "There have been postmarketing reports of increased INR and prothrombin time in patients receiving proton pump inhibitors , including Pantoprazole , and warfarin concomitantly .Increases in INR and prothrombin time may lead to abnormal bleeding and even death .", "label": "", "metadata": {}, "score": "49.97596"}
{"text": "There have been postmarketing reports of increased INR and prothrombin time in patients receiving proton pump inhibitors , including pantoprazole , and warfarin concomitantly .Increases in INR and prothrombin time may lead to abnormal bleeding and even death .", "label": "", "metadata": {}, "score": "49.97596"}
{"text": "N. Engl .J. Med .[ Google Scholar ] [ CrossRef ] .Block , G.A. ; Zaun , D. ; Smits , G. ; Persky , M. ; Brillhart , S. ; Nieman , K. ; Liu , J. ; St Peter , W.L. Cinacalcet hydrochloride treatment significantly improved all - cause and cardiovascular survival in a large cohort of hemodialysis patients .", "label": "", "metadata": {}, "score": "49.982788"}
{"text": "A stronger design would have been to compare PTX rates in patients receiving cinacalcet with rates in patients who did not .However , in the absence of available PTH levels , it was not possible to identify a control group that would have had the same severity of hyperparathyroidism and did not receive cinacalcet .", "label": "", "metadata": {}, "score": "50.052326"}
{"text": "These pharmacokinetic changes in hepatic - impaired patients result in minimal drug accumulation following once - daily , multiple - dose administration .No dosage adjustment is needed in patients with mild to severe hepatic impairment .", "label": "", "metadata": {}, "score": "50.07381"}
{"text": "These pharmacokinetic changes in hepatic - impaired patients result in minimal drug accumulation following once - daily , multiple - dose administration .No dosage adjustment is needed in patients with mild to severe hepatic impairment .", "label": "", "metadata": {}, "score": "50.07381"}
{"text": "Differing provisions from the publisher 's actual policy or licence agreement may be applicable . \" In some cases , Lomonte et al . have described the successful use of cinacalcet inducing the suppression of intact PTH secretion by the parathyroid glands [ 20].", "label": "", "metadata": {}, "score": "50.084213"}
{"text": "Serious adverse events include tetany , arrhythmias , and seizures .In most patients , treatment of hypomagnesemia required magnesium replacement and discontinuation of the PPI .", "label": "", "metadata": {}, "score": "50.26672"}
{"text": "Take the next dose at your regular time .Do not take two doses to try to make up for a missed dose .If you take too much pantoprazole sodium delayed - release tablets , call your doctor right away .", "label": "", "metadata": {}, "score": "50.363014"}
{"text": "Treatment at 5 to 150 mg / kg / day also produced gastric - fundic ECL cell hyperplasia .A 26-week p53 + /- transgenic mouse carcinogenicity study was not positive .", "label": "", "metadata": {}, "score": "50.415794"}
{"text": "Treatment at 5 to 150 mg / kg / day also produced gastric - fundic ECL cell hyperplasia .A 26-week p53 + /- transgenic mouse carcinogenicity study was not positive .", "label": "", "metadata": {}, "score": "50.415794"}
{"text": "In the CARE 2 study [ 31 ] , chronic HD patients from the United States were randomized to receive either calcium acetate or sevelamer HCl .", "label": "", "metadata": {}, "score": "50.419617"}
{"text": "Only slight to moderate increases in pantoprazole AUC ( 43 % ) and C max ( 26 % ) were found in elderly volunteers ( 64 to 76 years of age ) after repeated oral administration , compared with younger subjects .", "label": "", "metadata": {}, "score": "50.42531"}
{"text": "Pantoprazole is metabolized mainly by CYP2C19 and to minor extents by CYPs 3A4 , 2D6 , and 2C9 .Clopidogrel is metabolized to its active metabolite in part by CYP2C19 .", "label": "", "metadata": {}, "score": "50.706867"}
{"text": "( mg / week ) ; CC , Ca carbonate ( g / day ) ; S , sevelamer ( g / day ) ; C 30 ? , cinacalcet ( 30 mg every other day ) .", "label": "", "metadata": {}, "score": "50.78199"}
{"text": "No data on cardiovascular events other than death , fractures , or parathyroidectomy rates were available from either of these studies , making it impossible to draw conclusions on the impact of using sevelamer HCl instead of a calcium - based phosphate binder on such outcomes .", "label": "", "metadata": {}, "score": "50.861214"}
{"text": "The risk of fracture was increased in patients who received high - dose , defined as multiple daily doses , and long - term PPI therapy ( a year or longer ) .", "label": "", "metadata": {}, "score": "51.000294"}
{"text": "Treatment at 5 to 150 mg / kg / day also produced gastric fundic ECL cell hyperplasia .A 26-week p53 + /- transgenic mouse carcinogenicity study was not positive .", "label": "", "metadata": {}, "score": "51.109604"}
{"text": "Notably , calcitriol was introduced in patients 1 , 2 , 3 and 4 because these patients had previously , and continued to have , serum Ca levels below the lower limits advised by the NKF / K - DOQI guidelines [ 9].", "label": "", "metadata": {}, "score": "51.11048"}
{"text": "However , no data about the treatment with cinacalcet of relapses of SHPTH after PTx are available in literature .The aim of this single - centre prospective study was to evaluate the therapeutic efficacy of cinacalcet in this high - risk category of patients .", "label": "", "metadata": {}, "score": "51.127796"}
{"text": "17 PATIENT COUNSELING INFORMATION .Caution patients that pantoprazole sodium delayed - release tablets should not be split , crushed , or chewed .Tell patients that pantoprazole sodium delayed - release tablets should be swallowed whole , with or without food in the stomach .", "label": "", "metadata": {}, "score": "51.13389"}
{"text": "Unit dose package of 100 ( 10 x 10 ) NDC 0904 - 6235 - 61 .Storage .Store pantoprazole sodium delayed - release tablets at 20 \u00b0 -25 \u00b0 C ( 68 \u00b0 -77 \u00b0 F ) ; excursions permitted to 15 \u00b0 -30 \u00b0 C ( 59 \u00b0 -86 \u00b0 F ) .", "label": "", "metadata": {}, "score": "51.35854"}
{"text": "The study was designed to assess noninferiority , evaluating CAC using EBCT at 6 and 12 months after randomization .Before 1 year , 30 % of the patients in the sevelamer arm and 43 % in the calcium acetate arm dropped out .", "label": "", "metadata": {}, "score": "51.393135"}
{"text": "Read the Patient Information that comes with Pantoprazole before you start taking it and each time you get a refill .There may be new information .", "label": "", "metadata": {}, "score": "51.54954"}
{"text": "Geriatric .Only slight to moderate increases in pantoprazole AUC ( 43 % ) and Cmax ( 26 % ) were found in elderly volunteers ( 64 to 76 years of age ) after repeated oral administration , compared with younger subjects .", "label": "", "metadata": {}, "score": "51.562737"}
{"text": "Unfortunately , only intravenous vitamin D analogues were available in Li et al .[5 ] study , therefore use of phosphate binders , cinacalcet and oral vitamin D was not reported .", "label": "", "metadata": {}, "score": "51.628426"}
{"text": "Pharmacodynamic parameters were also measured and demonstrated that the change in inhibition of platelet aggregation ( induced by 5 \u00b5M ADP ) was correlated with the change in the exposure to clopidogrel active metabolite .", "label": "", "metadata": {}, "score": "51.64458"}
{"text": "5.1 Implications of Symptomatic Response .5.2 Hypersensitivity and Severe Skin Reactions .Anaphylaxis and other serious reactions such as erythema multiforme , Stevens - Johnson syndrome , and toxic epidermal necrolysis ( TEN ) have been reported with use of intravenous pantoprazole .", "label": "", "metadata": {}, "score": "51.752396"}
{"text": "Cinacalcet was maintained at 25 mg until iPTH was less than 150 pg / mL. The dosage of the phosphate binder and vitamin D sterols , either oral or intravenous calcitriol , was elastically titrated or discontinued temporarily according to iPTH and calcium phosphate product ( Ca \u00d7 P ) levels as per K / DOQI and KDIGO guidelines recommendation .", "label": "", "metadata": {}, "score": "51.811752"}
{"text": "J. Nephrol .[ Google Scholar ] [ CrossRef ] .Antonsen , J.E. ; Sherrard , D.J. ; Andress , D.L. A calcimimetic agent acutely suppresses parathyroid hormone levels in patients with chronic renal failure .", "label": "", "metadata": {}, "score": "51.861927"}
{"text": "Higher dose pharmacological use of vitamin D therapy through the activation of VDR has demonstrated its efficacy in suppressing hyperparathyroidism and several large observational studies have also shown survival advantage [ 10 , 11 , 12 ] .", "label": "", "metadata": {}, "score": "51.92389"}
{"text": "The data were expressed as mean?SD and as percentage .NS , not significant .Page 4 .Two other patients treated with cinacalcet ( one affected by carcinoma of the parathyroid glands and the other by nodular hyperplasia ) maintained serum levels of iPTH of 600pg / ml .", "label": "", "metadata": {}, "score": "52.014153"}
{"text": "You may report side effects to the FDA at 1 - 800-FDA-1088 .How should I store pantoprazole sodium delayed - release tablets ?", "label": "", "metadata": {}, "score": "52.330364"}
{"text": "Pharmacokinetic information in pediatric patients is approved for Wyeth Pharmaceuticals Inc. 's pantoprazole sodium delayed - release tablets .However , due to Wyeth Pharmaceuticals Inc. 's marketing exclusivity rights , this drug product is not labeled with that pediatric information .", "label": "", "metadata": {}, "score": "52.41293"}
{"text": "However , weight - normalized clearance values are similar in women and men .No dosage adjustment is recommended based on gender .In pediatric patients ages 1 through 16 years there were no clinically relevant effects of gender on clearance of pantoprazole , as shown by population pharmacokinetic analysis .", "label": "", "metadata": {}, "score": "52.41468"}
{"text": "There have been postmarketing reports of increased INR and prothrombin time in patients receiving proton pump inhibitors , including Pantoprazole , and warfarin concomitantly [ see Drug Interactions ( 7.2 ) ] .", "label": "", "metadata": {}, "score": "52.468742"}
{"text": "Because severe secondary hyperparathyroidism may not be completely controlled in all patients using cinacalcet and because some patients may not tolerate cinacalcet or would prefer to undergo a PTX , it is expected that rates of PTX would not fall indefinitely .", "label": "", "metadata": {}, "score": "52.47047"}
{"text": "However , at 48 hours after their last oral dose , patients treated with PROTONIX I.V. for Injection had a significantly lower mean basal acid output ( see Table 3 ) than those treated with placebo .", "label": "", "metadata": {}, "score": "52.482506"}
{"text": "11 DESCRIPTION .The active ingredient in Pantoprazole Sodium Delayed - Release Tablets , USP is a substituted benzimidazole , sodium 5-(difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridinyl)methyl ] sulfinyl]-1 H -benzimidazole sesquihydrate , a compound that inhibits gastric acid secretion .", "label": "", "metadata": {}, "score": "52.547783"}
{"text": "Despite the fact that the drop in PTX rates is visually convincing during the intervention period , we tested six different intervention dates and statistically significant results may be due to chance by multiple testing ( limited power precluded applying correction factors such as Bonferroni ) .", "label": "", "metadata": {}, "score": "52.599392"}
{"text": "11 DESCRIPTION .Therapeutic class : Proton Pump Inhibitor ( PPI ) .The active ingredient in PROTONIX I.V. ( intravenous pantoprazole sodium ) for Injection is a substituted benzimidazole , sodium 5-(difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridinyl)methyl ] sulfinyl]-1 H -benzimidazole , a compound that inhibits gastric acid secretion .", "label": "", "metadata": {}, "score": "52.6494"}
{"text": "Once gastric acid secretion was controlled , there was no evidence of tolerance during this 7 day study .In both studies , doses were adjusted to the individual patient need , but gastric acid secretion was controlled in greater than 80 % of patients by a starting regimen of 80 mg q12h .", "label": "", "metadata": {}, "score": "52.65726"}
{"text": "They will take cinacalcet once a day .Treatment will be monitored with frequent blood tests and imaging studies .Participants will continue to take cinacalcet once a day for 3 weeks .", "label": "", "metadata": {}, "score": "52.781155"}
{"text": "Soc .Nephrol .[ Google Scholar ] .Ross , E.A. ; Tian , J. ; Abboud , H. ; Hippensteel , R. ; Melnick , J.Z. ; Pradhan , R.S. ; Williams , L.A. ; Hamm , L.L. ; Sprague , S.M. Oral paricalcitol for the treatment of secondary hyperparathyroidism on hemodialysis or peritoneal dialysis .", "label": "", "metadata": {}, "score": "52.9144"}
{"text": "Additionally , cinalcalcet reimbursement was conditional on specific criteria as detailed previously , and physicians were encouraged to use vitamin D and phosphate binders to gain access to cinacalcet for their patients .", "label": "", "metadata": {}, "score": "52.964073"}
{"text": "Maintain healing of acid - related damage to the lining of the esophagus and helps prevent return of heartburn symptoms caused by GERD .Pantoprazole sodium delayed - release tablets has not been studied for treatment lasting longer than 1 year .", "label": "", "metadata": {}, "score": "52.974937"}
{"text": "Coadministration of atazanavir or nelfinavir with proton pump inhibitors is expected to substantially decrease atazanavir or nelfinavir plasma concentrations and may result in a loss of therapeutic effect and development of drug resistance .", "label": "", "metadata": {}, "score": "53.052048"}
{"text": "14.3 Pathological Hypersecretory Conditions Including Zollinger - Ellison Syndrome .In a multicenter , open - label trial of 35 patients with pathological hypersecretory conditions , such as Zollinger - Ellison syndrome , with or without multiple endocrine neoplasia - type I , Pantoprazole successfully controlled gastric acid secretion .", "label": "", "metadata": {}, "score": "53.113503"}
{"text": "Calcimimetic agent , such as cinacalcet , which not only allosterically enhances sensitivity to CaSR , but also increases the expression of VDR of the parathyroid gland , became available since its approval in 2004 [ 14 ] .", "label": "", "metadata": {}, "score": "53.133232"}
{"text": "PANTOPRAZOLE sodium delayed - release tablets , USP Initial U.S. approval : 2000 .Information describing use in pediatric patients with erosive esophagitis associated with GERD is approved for Wyeth Pharmaceuticals Inc. 's pantoprazole sodium delayed - release tablets .", "label": "", "metadata": {}, "score": "53.134537"}
{"text": "If needed , your doctor may prescribe an additional 8 weeks of Pantoprazole .Maintain healing of acid - related damage to the lining of the esophagus and helps prevent return of heartburn symptoms caused by GERD .", "label": "", "metadata": {}, "score": "53.2988"}
{"text": "If you do not know if your medicines are PPIs , please ask your doctor .What should I tell my doctor before taking Pantoprazole ?", "label": "", "metadata": {}, "score": "53.34308"}
{"text": "PANTOPRAZOLE Sodium delayed - release tablets USP Initial U.S. Approval : 2000 .Information describing use in pediatric patients with erosive esophagitis associated with GERD is approved for Wyeth Pharmaceuticals Inc. 's pantoprazole sodium delayed - release tablets .", "label": "", "metadata": {}, "score": "53.408485"}
{"text": "Pantoprazole absorption is not affected by concomitant administration of antacids .Administration of Pantoprazole Sodium Delayed - Release Tablets with food may delay its absorption up to 2 hours or longer ; however , the C max and the extent of pantoprazole absorption ( AUC ) are not altered .", "label": "", "metadata": {}, "score": "53.495945"}
{"text": "- administration of atazanavir or nelfinavir with proton pump inhibitors is expected to substantially decrease atazanavir or nelfinavir plasma concentrations and may result in a loss of therapeutic effect and development of drug resistance . 7.2", "label": "", "metadata": {}, "score": "53.569313"}
{"text": "Caution patients that Pantoprazole Sodium Delayed - Release Tablets should not be split , crushed , or chewed .Tell patients that Pantoprazole Sodium Delayed - Release Tablets should be swallowed whole , with or without food in the stomach .", "label": "", "metadata": {}, "score": "53.706127"}
{"text": "Pantoprazole sodium delayed - release tablets USP are indicated for maintenance of healing of erosive esophagitis and reduction in relapse rates of daytime and nighttime heartburn symptoms in adult patients with GERD .", "label": "", "metadata": {}, "score": "53.741264"}
{"text": "There was no renal excretion of unchanged pantoprazole .After repeated I.V. administration in elderly subjects ( 65 to 76 years of age ) , pantoprazole AUC and elimination half - life values were similar to those observed in younger subjects .", "label": "", "metadata": {}, "score": "53.91504"}
{"text": "On Day 5 , the mean AUC of the active metabolite of clopidogrel was reduced by approximately 14 % ( geometric mean ratio was 86 % , with 90 % CI of 79 to 93 % ) when pantoprazole was coadministered with clopidogrel as compared to clopidogrel administered alone .", "label": "", "metadata": {}, "score": "53.91889"}
{"text": "On Day 5 , the mean AUC of the active metabolite of clopidogrel was reduced by approximately 14 % ( geometric mean ratio was 86 % , with 90 % CI of 79 to 93 % ) when pantoprazole was coadministered with clopidogrel as compared to clopidogrel administered alone .", "label": "", "metadata": {}, "score": "53.91889"}
{"text": "Thrombophlebitis is associated with the administration of intravenous pantoprazole ( 5.3 ) .Zinc supplementation should be considered in patients treated with PROTONIX I.V. for Injection who are prone to zinc deficiency .", "label": "", "metadata": {}, "score": "54.01645"}
{"text": "Take the next dose at your regular time .Do not take two doses to try to make up for a missed dose .If you take too much Pantoprazole , call your doctor right away .", "label": "", "metadata": {}, "score": "54.10383"}
{"text": "This data shows a clear shift to lower dosing of calcium - based binders and an increasing utilization of non - calcium - based binders such as sevelamer and lanthanum .", "label": "", "metadata": {}, "score": "54.147873"}
{"text": "A further paper examined the effect of these two oral phosphate - binders on valvular calcification in 132 hemodialysis patients , concluding that after a one - year observation period , sevelamer had checked the progression of vascular and valvular calcifications in almost 50 % of patients [ 25 ] .", "label": "", "metadata": {}, "score": "54.206078"}
{"text": "Talk to your doctor if you are pregnant or plan to become pregnant .are breastfeeding or planning to breastfeed .Pantoprazole sodium delayed - release tablets may pass into your milk .", "label": "", "metadata": {}, "score": "54.220215"}
{"text": "Lindberg JS , Culleton B , Wong G et al .Cinacalcet HCl , an oral calcimimetic agent for the treatment of secondary hyper- parathyroidism in hemodialysis and peritoneal dialysis : A randomized , double - blind , Nephrol 2005 ; 16 : 800 - 807 13 .", "label": "", "metadata": {}, "score": "54.381165"}
{"text": "Enterochromaffin - Like ( ECL ) Cell Effects .In a nonclinical study in Sprague - Dawley rats , lifetime exposure ( 24 months ) to pantoprazole at doses of 0.5 to 200 mg / kg / day resulted in dose - related increases in gastric ECL cell proliferation and gastric neuroendocrine ( NE)-cell tumors .", "label": "", "metadata": {}, "score": "54.384083"}
{"text": "However , no formal drug interaction studies of methotrexate with PPIs have been conducted [ see Warnings and Precautions ( 5.8 ) ] . 8 USE IN SPECIFIC POPULATIONS . 8.1 Pregnancy .", "label": "", "metadata": {}, "score": "54.401222"}
{"text": "Fasting serum gastrin levels were assessed in two double - blind studies of the acute healing of erosive esophagitis ( EE ) in which 682 patients with gastroesophageal reflux disease ( GERD ) received 10 , 20 , or 40 mg of Pantoprazole for up to 8 weeks .", "label": "", "metadata": {}, "score": "54.47029"}
{"text": "Pantoprazole and its metabolites are excreted in the milk of rats .Pantoprazole excretion in human milk has been detected in a study of a single nursing mother after a single 40 mg oral dose .", "label": "", "metadata": {}, "score": "54.520767"}
{"text": "Pantoprazole and its metabolites are excreted in the milk of rats .Pantoprazole excretion in human milk has been detected in a study of a single nursing mother after a single 40 mg oral dose .", "label": "", "metadata": {}, "score": "54.520767"}
{"text": "Pantoprazole and its metabolites are excreted in the milk of rats .Pantoprazole excretion in human milk has been detected in a study of a single nursing mother after a single 40 mg oral dose .", "label": "", "metadata": {}, "score": "54.520767"}
{"text": "The table of Other Adverse Events summarizes the most frequent non - serious occurrences of adverse events .The number of participants at risk includes subjects who received at least 1 dose of investigational product .", "label": "", "metadata": {}, "score": "54.996902"}
{"text": "J Am Soc Nephrol 2003 ; 14 : 575 - 583 11 .Block GA , Martin KJ , de Francisco AL et al .Cinacalcet for secondary hyperparathyroidism in patients receving hemo- dialysis .", "label": "", "metadata": {}, "score": "55.026123"}
{"text": "N Engl J Med 2004 , 350 ( 15 ) : 1516 - 1525 .PubMed View Article .Cunningham J , Danese M , Olson K , Klassen P , Chertow GM : Effects of the calcimimetic cinacalcet HCl on cardiovascular disease , fracture , and health - related quality of life in secondary hyperparathyroidism .", "label": "", "metadata": {}, "score": "55.039497"}
{"text": "After oral administration there is a modest increase in pantoprazole AUC and C max in women compared to men .However , weight - normalized clearance values are similar in women and men .", "label": "", "metadata": {}, "score": "55.182217"}
{"text": "Figure 1 .Figure 2 .Figure 2 .The Use and Dosage of Phosphate Binder and Calcitriol .The usage of of phosphate binder and calcitriol during treatment period is summarized in Table 3 .", "label": "", "metadata": {}, "score": "55.393578"}
{"text": "Open - label Dose - titration Study of the Tolerability and Efficacy of Cinacalcet to Treat Fibroblast Growth Factor 23 ( FGF23)-Mediated Hypophosphatemia .Or , diagnosis of a non - genetic form of FGF23-mediated hypophosphatemia , i.e. tumor - induced osteomalacia ( TIO ) .", "label": "", "metadata": {}, "score": "55.40507"}
{"text": "These are not all the possible side effects with Pantoprazole .Talk with your doctor or pharmacist if you have any questions about side effects .", "label": "", "metadata": {}, "score": "55.42911"}
{"text": "Following the administration of PROTONIX I.V. for Injection , the serum concentration of pantoprazole declines biexponentially with a terminal elimination half - life of approximately one hour .", "label": "", "metadata": {}, "score": "55.44433"}
{"text": "At baseline , there was no significant difference in any biochemical target .None of the subjects in either group received native vitamin D or parathyroidectomy during the study period .", "label": "", "metadata": {}, "score": "55.502018"}
{"text": "You can take Pantoprazole sodium delayed - release tablets with food or on an empty stomach .Swallow Pantoprazole sodium delayed - release tablets whole .", "label": "", "metadata": {}, "score": "55.564007"}
{"text": "Reproduction studies have been performed in rats at oral doses up to 88 times the recommended human dose and in rabbits at oral doses up to 16 times the recommended human dose and have revealed no evidence of impaired fertility or harm to the fetus due to pantoprazole .", "label": "", "metadata": {}, "score": "55.59851"}
{"text": "Reproduction studies have been performed in rats at oral doses up to 88 times the recommended human dose and in rabbits at oral doses up to 16 times the recommended human dose and have revealed no evidence of impaired fertility or harm to the fetus due to pantoprazole .", "label": "", "metadata": {}, "score": "55.59851"}
{"text": "In clinical studies of Zollinger - Ellison Syndrome , adverse reactions reported in 35 patients taking Pantoprazole 80 mg / day to 240 mg / day for up to 2 years were similar to those reported in adult patients with GERD . 6.2", "label": "", "metadata": {}, "score": "55.626057"}
{"text": "This leaflet does not take the place of talking with your doctor about your medical condition or your treatment .What are pantoprazole sodium delayed - release tablets ?", "label": "", "metadata": {}, "score": "55.70182"}
{"text": "Possible side effects include : .Nausea .Vomiting .Transient low blood calcium level .Diuretics .Furosemide ( Lasix ) .Bumetanide ( Bumex ) .", "label": "", "metadata": {}, "score": "55.81543"}
{"text": "1.2 Maintenance of Healing of Erosive Esophagitis .Pantoprazole is indicated for maintenance of healing of erosive esophagitis and reduction in relapse rates of daytime and nighttime heartburn symptoms in adult patients with GERD .", "label": "", "metadata": {}, "score": "55.978577"}
{"text": "Pantoprazole peak serum concentration ( C max ) and area under the serum concentration - time curve ( AUC ) increase in a manner proportional to intravenous doses from 10 mg to 80 mg .", "label": "", "metadata": {}, "score": "56.13932"}
{"text": "Since cinacalcet is not the only factor that changed over the study period , phosphate binders ( sevelamer , lanthanum , calcium - containing , and magnesium and/or aluminium - containing ) and vitamin D use was also measured .", "label": "", "metadata": {}, "score": "56.24951"}
{"text": "The study was extended because the mortality rate in the control group was lower than expected .Only 1068 patients completed the study , and there were no differences in all - cause or cause - specific mortality rates when comparing sevelamer HCl ( mortality rate 15.0 per 100 patient - years ) with calcium - treated patients ( 16.1 per 100 patient - years ) .", "label": "", "metadata": {}, "score": "56.253998"}
{"text": "Furthermore , hospitalizations from CVD as ascertained from the administrative data did not differ , lending no support to the study 's hypothesis that sevelamer HCl reduces cardiovascular disease ( CVD ) morbidity .", "label": "", "metadata": {}, "score": "56.29277"}
{"text": "Pantoprazole is indicated in adults for the short - term treatment ( up to 8 weeks ) in the healing and symptomatic relief of erosive esophagitis .", "label": "", "metadata": {}, "score": "56.31889"}
{"text": "No dosage adjustment is needed in patients with mild to severe hepatic impairment .Doses higher than 40 mg / day have not been studied in hepatically impaired patients .", "label": "", "metadata": {}, "score": "56.33559"}
{"text": "This Patient Information leaflet provides a summary of the most important information about pantoprazole sodium delayed - release tablets .For more information , ask your doctor .", "label": "", "metadata": {}, "score": "56.66297"}
{"text": "Many drugs which are excreted in human milk have a potential for serious adverse reactions in nursing infants .Based on the potential for tumorigenicity shown for pantoprazole in rodent carcinogenicity studies , a decision should be made whether to discontinue nursing or to discontinue the drug , taking into account the benefit of the drug to the mother .", "label": "", "metadata": {}, "score": "56.739204"}
{"text": "Many drugs which are excreted in human milk have a potential for serious adverse reactions in nursing infants .Based on the potential for tumorigenicity shown for pantoprazole in rodent carcinogenicity studies , a decision should be made whether to discontinue nursing or to discontinue the drug , taking into account the benefit of the drug to the mother .", "label": "", "metadata": {}, "score": "56.739204"}
{"text": "Many drugs which are excreted in human milk have a potential for serious adverse reactions in nursing infants .Based on the potential for tumorigenicity shown for pantoprazole in rodent carcinogenicity studies , a decision should be made whether to discontinue nursing or to discontinue the drug , taking into account the benefit of the drug to the mother .", "label": "", "metadata": {}, "score": "56.739204"}
{"text": "Parenteral routes of administration other than intravenous are not recommended .PROTONIX I.V. for Injection may be administered intravenously through a dedicated line or through a Y - site .", "label": "", "metadata": {}, "score": "56.78666"}
{"text": "For adult patients who are CYP2C19 poor metabolizers , no dosage adjustment is needed .Poor metabolizers exhibited approximately 10-fold lower apparent oral clearance compared to extensive metabolizers .", "label": "", "metadata": {}, "score": "56.79196"}
{"text": "There have been reports of false positive urine screening tests for tetrahydrocannabinol ( THC ) in patients receiving proton pump inhibitors .An alternative confirmatory method should be considered to verify positive results . 8 USE IN SPECIFIC POPULATIONS . 8.1 Pregnancy .", "label": "", "metadata": {}, "score": "56.82351"}
{"text": "Prevention and treatment of secondary hyperparathyroidism remain a continuous challenge for the nephrologist , despite availability of phosphate binders , active vitamin D analogues and more recently , cinacalcet .", "label": "", "metadata": {}, "score": "56.836082"}
{"text": "[34 ] of a ten - year period of observation provided encouraging results for the use of sevelamer due to the improvements produced in vascular calcifications , bone physiology , and a potential positive trend in mortality rates for hemodialysis patients .", "label": "", "metadata": {}, "score": "56.96142"}
{"text": "Pediatric .Pharmacokinetic information in pediatric patients is approved for Wyeth Pharmaceuticals Inc. 's pantoprazole sodium delayed - release tablets .However , due to Wyeth Pharmaceuticals Inc. 's marketing exclusivity rights , this drug product is not labeled with that pediatric information .", "label": "", "metadata": {}, "score": "57.248196"}
{"text": "If you have trouble swallowing a pantoprazole sodium 40 mg tablet , you can take two 20 mg tablets instead .Do not split , chew , or crush pantoprazole sodium delayed - release tablets .", "label": "", "metadata": {}, "score": "57.287994"}
{"text": "In most patients , treatment of hypomagnesemia required magnesium replacement and discontinuation of the PPI .5.10 Interference with Urine Screen for THC .5.11 Concomitant use of PROTONIX with Methotrexate .", "label": "", "metadata": {}, "score": "57.356064"}
{"text": "The effectiveness of Pantoprazole for treating symptomatic GERD in pediatric patients has not been established .Information describing use in pediatric patients with erosive esophagitis associated with GERD is approved for Wyeth Pharmaceuticals Inc. 's pantoprazole sodium delayed - release tablets .", "label": "", "metadata": {}, "score": "57.464508"}
{"text": "4 , pp .1125 - 1130 , 2008 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at PubMed .J. Delmez , G. Block , J. Robertson et al . , \" A randomized , double - blind , crossover design study of sevelamer hydrochloride and sevelamer carbonate in patients on hemodialysis , \" Clinical Nephrology , vol .", "label": "", "metadata": {}, "score": "57.537895"}
{"text": "Among the 52 patients under- going PTx , five died owing to clinical causes not related to PTx , seven underwent renal transplantation .Among the remaining 40 patients , four underwent a second PTx because of either the persistence or the precocious relapse ( in the first six months after the operation ) of SHPTH .", "label": "", "metadata": {}, "score": "57.56012"}
{"text": "Equivocal results were observed in the in vivo rat liver DNA covalent binding assay .13.2 Animal Pharmacology and/or Toxicology .Studies in neonatal / juvenile and adult rats and dogs were performed .", "label": "", "metadata": {}, "score": "57.59624"}
{"text": "Full to partial recovery of these effects were noted in animals of both age groups following a recovery period .Reproductive Toxicology Studies .14 CLINICAL STUDIES .", "label": "", "metadata": {}, "score": "57.670116"}
{"text": "We can not support the direct effect of combined therapy on bone turnover , which is an important component of mineral and bone metabolism .Therefore , further prospective long - term studies are necessary to confirm the beneficial effects of a combined therapy of low - dose cinacalcet and calcitriol on renal bone pathology .", "label": "", "metadata": {}, "score": "57.702972"}
{"text": "Equivocal results were observed in the in vivo rat liver DNA covalent binding assay .13.2 Animal Toxicology and/or Pharmacology .Studies in neonatal / juvenile and adult rats and dogs were performed .", "label": "", "metadata": {}, "score": "57.74494"}
{"text": "Equivocal results were observed in the in vivo rat liver DNA covalent binding assay .13.2 Animal Toxicology and/or Pharmacology .Studies in neonatal / juvenile and adult rats and dogs were performed .", "label": "", "metadata": {}, "score": "57.74494"}
{"text": "10 OVERDOSAGE .Spontaneous post - marketing reports of overdose are generally within the known safety profile of pantoprazole sodium .Pantoprazole is not removed by hemodialysis .", "label": "", "metadata": {}, "score": "57.75653"}
{"text": "Transition from oral to intravenous and from intravenous to oral formulations of gastric acid inhibitors should be performed in such a manner to ensure continuity of effect of suppression of acid secretion .", "label": "", "metadata": {}, "score": "57.79355"}
{"text": "For more information , call toll - free 1 - 888 - 375 - 3784 .What are the ingredients in pantoprazole sodium delayed - release tablets ?", "label": "", "metadata": {}, "score": "57.830826"}
{"text": "No data about the treatment with cinacalcet of relapses of SHPTH after PTx are available in literature .Thus , the successful response of our patients to cinacalcet is the in vivo mirror of the in vitro evidence of the suppressive effect of cinacalcet on parathyroid cells with patholo- gically reduced CaSR levels [ 23].", "label": "", "metadata": {}, "score": "57.879044"}
{"text": "Tell your doctor if you get any of the following symptoms with pantoprazole sodium delayed - release tablets .rash . face swelling .throat tightness . difficult breathing .", "label": "", "metadata": {}, "score": "58.034046"}
{"text": "A carbonated form of sevelamer featuring a similar efficacy in control of hyperphosphatemia and which does not worsen metabolic acidosis , as occurs with the HCl preparation , has recently been introduced onto the market [ 48 , 49 ] .", "label": "", "metadata": {}, "score": "58.041153"}
{"text": "The effectiveness of pantoprazole sodium for treating symptomatic GERD in pediatric patients has not been established .Information describing use in pediatric patients with erosive esophagitis associated with GERD is approved for Wyeth Pharmaceuticals Inc. 's pantoprazole sodium delayed - release tablets .", "label": "", "metadata": {}, "score": "58.060196"}
{"text": "Pantoprazole does not accumulate , and its pharmacokinetics are unaltered with multiple daily dosing .Following oral administration , the serum concentration of pantoprazole declines biexponentially , with a terminal elimination half - life of approximately one hour .", "label": "", "metadata": {}, "score": "58.226364"}
{"text": "Time between the two periods was not considered in this analysis .As a second sensitivity analysis , ARIMA and Poisson regression analyses were redone by excluding periods of time where patients were not covered by the RAMQ drug plan .", "label": "", "metadata": {}, "score": "58.26252"}
{"text": "Soc .Nephrol .[ Google Scholar ] [ CrossRef ] .Teng , M. ; Wolf , M. ; Lowrie , E. ; Ofsthun , N. ; Lazarus , J.M. ; Thadhani , R. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy .", "label": "", "metadata": {}, "score": "58.307034"}
{"text": "Pantoprazole sodium delayed - release tablet is used in adults for : .Up to 8 weeks for short - term treatment of acid - related damage to the lining of the esophagus ( erosive esophagitis ) caused by gastroesophageal reflux disease ( GERD ) .", "label": "", "metadata": {}, "score": "58.4214"}
{"text": "Pantoprazole is extensively metabolized in the liver through the cytochrome P450 ( CYP ) system .Pantoprazole metabolism is independent of the route of administration ( intravenous or oral ) .", "label": "", "metadata": {}, "score": "58.437355"}
{"text": "An interesting study [ 28 ] examining the clinical outcomes in a smaller group of 109 incident HD patients ( patients new to dialysis , 64 diabetics and 45 non diabetics ) randomized to either sevelamer HCl or calcium - based binder followed up patients for a period of 18 months .", "label": "", "metadata": {}, "score": "58.454075"}
{"text": "A possible bias resulted from the limited ( 90 days ) followup of discontinued patients , as well as a lack of documentation of baseline biochemical parameters and AEs .", "label": "", "metadata": {}, "score": "58.514954"}
{"text": "Concomitant use of atazanavir or nelfinavir with proton pump inhibitors is not recommended .Coadministration of atazanavir or nelfinavir with proton pump inhibitors is expected to substantially decrease atazanavir or nelfinavir plasma concentrations and may result in a loss of therapeutic effect and development of drug resistance . 7.2", "label": "", "metadata": {}, "score": "58.554356"}
{"text": "Due to its effects on gastric acid secretion , pantoprazole can reduce the absorption of drugs where gastric pH is an important determinant of their bioavailability .", "label": "", "metadata": {}, "score": "58.560425"}
{"text": "12 CLINICAL PHARMACOLOGY .12.1 Mechanism of Action .Pantoprazole is a proton pump inhibitor ( PPI ) that suppresses the final step in gastric acid production by covalently binding to the ( H + , K + ) -ATPase enzyme system at the secretory surface of the gastric parietal cell .", "label": "", "metadata": {}, "score": "58.610283"}
{"text": "12 CLINICAL PHARMACOLOGY .12.1 Mechanism of Action .Pantoprazole is a proton pump inhibitor ( PPI ) that suppresses the final step in gastric acid production by covalently binding to the ( H + , K + ) -ATPase enzyme system at the secretory surface of the gastric parietal cell .", "label": "", "metadata": {}, "score": "58.610283"}
{"text": "A positive and significant correlation was found between nodular volume with ethanol injected and time from parathyroidectomy .Only one patient required hospitalization due to severe hypocalcaemia .", "label": "", "metadata": {}, "score": "58.681664"}
{"text": "HIGHLIGHTS OF PRESCRIBING INFORMATION .These highlights do not include all the information needed to use pantoprazole sodium delayed - release tablets USP safely and effectively .", "label": "", "metadata": {}, "score": "58.736797"}
{"text": "or oral or paricalcitol i.v .at the end of the dialysis session ) .Study procedures Serum levels of albumin , iPTH , Ca , P and alkaline phos- phatase ( ALP ) were determined monthly 12h after the administrationof cinacalcet . albumin , Ca , P and ALP were measured by routine automated methods .", "label": "", "metadata": {}, "score": "58.819412"}
{"text": "Iron supplements .Ampicillin antibiotics .Methotrexate .Ask your doctor if you are not sure if any of your medicines are the kind listed above .", "label": "", "metadata": {}, "score": "58.851643"}
{"text": "None declared .References 1 .Uren \u02dc a P , Basile C , Grateau G et al .Short - term effects of parathyroidectomy on plasma biochemistry in chronic uremia .", "label": "", "metadata": {}, "score": "58.894135"}
{"text": "Pathological Hypersecretory Conditions Including Zollinger - Ellison Syndrome .Adults .Doses up to 240 mg daily have been administered .Pediatric dosing information in pediatric patients ages five years and older with erosive esophagitis associated with GERD is approved for Wyeth Pharmaceuticals Inc. 's pantoprazole sodium delayed - release tablets .", "label": "", "metadata": {}, "score": "58.935635"}
{"text": "Pantoprazole Sodium Delayed - Release Tablets USP .Pantoprazole sodium delayed - release tablets USP should be swallowed whole , with or without food in the stomach .", "label": "", "metadata": {}, "score": "58.982933"}
{"text": "What are the possible side effects of Pantoprazole ?Serious allergic reactions .Tell your doctor if you get any of the following symptoms with Pantoprazole . rash . face swelling .", "label": "", "metadata": {}, "score": "59.090126"}
{"text": "Especially tell your doctor if you take : .Warfarin ( Coumadin , Athrombin - K , Jantoven , Panwarfin ) .Ketoconazole ( Nizoral ) .", "label": "", "metadata": {}, "score": "59.16543"}
{"text": "Pantoprazole Sodium Delayed - Release Tablets , USP are supplied as 20 mg white , oval biconvex delayed - release tablets imprinted in black ink with \" KU \" on one side and \" 180 \" on the other side and are available as follows : .", "label": "", "metadata": {}, "score": "59.187088"}
{"text": "When administered through a Y - site , PROTONIX I.V. for Injection is compatible with the following solutions : 5 % Dextrose Injection , USP , 0.9 % Sodium Chloride Injection , USP , or Lactated Ringer 's Injection , USP .", "label": "", "metadata": {}, "score": "59.190994"}
{"text": "For cinacalcet to be reimbursed for a given patient , the prescriber would need to obtain a prior authorization from the provincial drug plan by filling a form detailing those criteria .", "label": "", "metadata": {}, "score": "59.234165"}
{"text": "Pantoprazole does not accumulate , and its pharmacokinetics are unaltered with multiple daily dosing .Following oral or intravenous administration , the serum concentration of pantoprazole declines biexponentially , with a terminal elimination half - life of approximately one hour .", "label": "", "metadata": {}, "score": "59.258522"}
{"text": "In pediatric patients ages 1 through 16 years there were no clinically relevant effects of gender on clearance of pantoprazole , as shown by population pharmacokinetic analysis .", "label": "", "metadata": {}, "score": "59.357162"}
{"text": "Genomics 2005 , 15 , 29 - 34 .[ Google Scholar ] [ CrossRef ] .Li , D. ; Shao , L. ; Zhou , H. ; Jiang , W. ; Zhang , W. ; Xu , Y. The efficacy of cinacalcet combined with conventional therapy on bone and mineral metabolism in dialysis patients with secondary hyperparathyroidism : A meta - analysis .", "label": "", "metadata": {}, "score": "59.486053"}
{"text": "Zollinger - Ellison Syndrome .In clinical studies of Zollinger - Ellison Syndrome , adverse reactions reported in 35 patients taking pantoprazole sodium 80 mg / day to 240 mg / day for up to 2 years were similar to those reported in adult patients with GERD .", "label": "", "metadata": {}, "score": "59.74187"}
{"text": "Clinical study information in pediatric patients ages five years through 16 years with erosive esophagitis associated with GERD is approved for Wyeth Pharmaceuticals Inc. 's pantoprazole sodium delayed - release tablets .", "label": "", "metadata": {}, "score": "59.824684"}
{"text": "Clinical study information in pediatric patients ages five years through 16 years with erosive esophagitis associated with GERD is approved for Wyeth Pharmaceuticals Inc. 's pantoprazole sodium delayed - release tablets .", "label": "", "metadata": {}, "score": "59.824684"}
{"text": "The treatment group included four cases of nodular hyperplasia and two cases of carcinoma of parathyroid glands , whereas the control group included four cases of nodular hyperplasia and two cases of diffuse hyperplasia .", "label": "", "metadata": {}, "score": "59.924534"}
{"text": "Cinacalcet is a novel agent that increases sensitivity to the calcium - sensing receptor and is approved for control of UHPT .Nevertheless , cinacalcet is costly and information regarding efficacy of low - dose cinacalcet on UHPT is limited .", "label": "", "metadata": {}, "score": "60.013687"}
{"text": "Doses were initially titrated to the individual patient needs , and adjusted in some patients based on the clinical response with time [ see Dosage and Administration ( 2 ) ] .", "label": "", "metadata": {}, "score": "60.054733"}
{"text": "Doses were initially titrated to the individual patient needs , and adjusted in some patients based on the clinical response with time [ see Dosage and Administration ( 2 ) ] .", "label": "", "metadata": {}, "score": "60.054733"}
{"text": "Furthermore , this therapy is associated with improvement in hyperphosphatemia and hypercalcemia .Keywords : . cinacalcet ; uremic hyperparathyroidism ; dialysis ; parathyroid hormone .", "label": "", "metadata": {}, "score": "60.060158"}
{"text": "What are the ingredients in Pantoprazole ?Active ingredient : pantoprazole sodium sesquihydrate .Inactive ingredients in Pantoprazole Sodium Delayed - Release Tablets : black iron oxide , crospovidone , glyceryl behenate , hypromellose , isopropyl alcohol , lactose monohydrate , methacrylic acid copolymer dispersion , propylene glycol , talc , titanium dioxide , and triethyl citrate .", "label": "", "metadata": {}, "score": "60.108505"}
{"text": "Placebo .Participants were given matching placebo tablets compared to the cinacalcet group .Aborigine .Other .History of Diabetes Stratification Factor [ 1 ] [ units : Participants ] .", "label": "", "metadata": {}, "score": "60.25431"}
{"text": "Rare gastrointestinal tumors associated with pantoprazole treatment included an adenocarcinoma of the duodenum at 50 mg / kg / day and benign polyps and adenocarcinomas of the gastric fundus at 200 mg / kg / day .", "label": "", "metadata": {}, "score": "60.266357"}
{"text": "Finally , medication use among patients covered by private drug plans who are generally younger patients ( an important risk factor for severe secondary hyperparathyroidism ) could not be assessed .", "label": "", "metadata": {}, "score": "60.28785"}
{"text": "The relevance of these findings to tumor development in humans is unknown [ see Nonclinical Toxicology ( 13.1 ) ] . 6ADVERSE REACTIONS .Because clinical trials are conducted under widely varying conditions , adverse reaction rates observed in the clinical trials of a drug can not be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice .", "label": "", "metadata": {}, "score": "60.504616"}
{"text": "Do not change your dose or stop pantoprazole sodium delayed - release tablets without talking to your doctor .If you forget to take a dose of pantoprazole sodium delayed - release tablets , take it as soon as you remember .", "label": "", "metadata": {}, "score": "60.536"}
{"text": "Kidney Int .[ Google Scholar ] .Goodman , W.G. ; Hladik , G.A. ; Turner , S.A. ; Blaisdell , P.W. ; Goodkin , D.A. ; Liu , W. ; Barri , Y.M. ; Cohen , R.M. ; Coburn , J.W. The Calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism .", "label": "", "metadata": {}, "score": "60.573837"}
{"text": "Hemodial Int 2007 , 11 ( 1 ) : 62 - 71 .PubMed View Article .Daugirdas JT , Finn WF , Emmett M , Chertow GM : The phosphate binder equivalent dose .", "label": "", "metadata": {}, "score": "60.5852"}
{"text": "13.1 Carcinogenesis , Mutagenesis , Impairment of Fertility .In a 24-month carcinogenicity study , Sprague - Dawley rats were treated orally with doses of 0.5 to 200 mg / kg / day , about 0.1 to 40 times the exposure on a body surface area basis of a 50 kg person dosed at 40 mg / day .", "label": "", "metadata": {}, "score": "60.592144"}
{"text": "[ 35 ] studied a group of 45 hemodialysis patients treated with sevelamer and 130 untreated subjects ; patients receiving sevelamer had significantly lower carotid intima media thickness and lower low - density lipoprotein cholesterol levels .", "label": "", "metadata": {}, "score": "60.596413"}
{"text": "Infections and Infestations : Clostridium difficile associated diarrhea . 7 DRUG INTERACTIONS .7.1 Interference with Antiretroviral Therapy .Concomitant use of atazanavir or nelfinavir with proton pump inhibitors is not recommended .", "label": "", "metadata": {}, "score": "60.716866"}
{"text": "Despite not being widely available before June 2006 , carefully selected patients could have received cinacalcet from Amgen or private insurance companies .In the context where cinacalcet was probably given to patients who would otherwise have undergone a PTX and because the annual counts of PTX ranged from 29 to 57 before 2005 , only a few patients receiving cinacalcet could have highly influenced the observed PTX rates .", "label": "", "metadata": {}, "score": "60.7599"}
{"text": "Rx 8 .Rx 9 .Rx 10 .Rx 11 .Rx 12 .C , cinacalcet ( mg / day ) ; CTR , calcitriol per os ( mg / day ) ; CTRv , calcitriol i.v .", "label": "", "metadata": {}, "score": "60.790207"}
{"text": "13 NONCLINICAL TOXICOLOGY .13.1 Carcinogenesis , Mutagenesis , Impairment Of Fertility .In a 24-month carcinogenicity study , Sprague - Dawley rats were treated orally with doses of 0.5 to 200 mg / kg / day , about 0.1 to 40 times the exposure on a body surface area basis of a 50 kg person dosed at 40 mg / day .", "label": "", "metadata": {}, "score": "60.922207"}
{"text": "Pediatric dosing information in pediatric patients ages five years and older with erosive esophagitis associated with GERD is approved for Wyeth Pharmaceuticals Inc. 's pantoprazole sodium delayed - release tablets .", "label": "", "metadata": {}, "score": "60.93129"}
{"text": "Pantoprazole Sodium Delayed - Release Tablets are prepared as enteric - coated tablets so that absorption of pantoprazole begins only after the tablet leaves the stomach .", "label": "", "metadata": {}, "score": "60.958458"}
{"text": "Pantoprazole sodium delayed - release tablets are prepared as enteric - coated tablets so that absorption of pantoprazole begins only after the tablet leaves the stomach .", "label": "", "metadata": {}, "score": "60.958458"}
{"text": "The percentage of patients on vitamin D was stable until 2005 , and then started to rise .The average daily dose of alfacalcidol increased only very slowly however , and calcitriol daily dose remained stable .", "label": "", "metadata": {}, "score": "60.9787"}
{"text": "16 HOW SUPPLIED / STORAGE AND HANDLING .How Supplied .Pantoprazole sodium delayed - release tablets USP 40 mg are yellow , round , biconvex coated tablets printed with \" R333 \" on one side with black ink and plain on the other side .", "label": "", "metadata": {}, "score": "61.04441"}
{"text": "Recent evidence has suggested that non - calcium - based phosphate binding agents such as sevelamer hydrochloride , sevelamer carbonate , and lanthanum carbonate may attenuate cardiovascular calcifications compared with calcium - based phosphate binders .", "label": "", "metadata": {}, "score": "61.079964"}
{"text": "414 - 422 , 2011 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at PubMed .G. M. Chertow , P. Raggi , J. T. McCarthy et al . , \" The effects of sevelamer and calcium acetate on proxies of atherosclerotic and arteriosclerotic vascular disease in hemodialysis patients , \" American Journal of Nephrology , vol .", "label": "", "metadata": {}, "score": "61.21939"}
{"text": "The dosage of phosphate binder and vitamin D sterols and biochemical data such as corrected serum calcium , phosphorous , iPTH , alkaline phosphatase and hemoglobin were collected and recorded monthly for a successive 6 months before and after commencing UHPT therapy .", "label": "", "metadata": {}, "score": "61.46216"}
{"text": "HIGHLIGHTS OF PRESCRIBING INFORMATION .These highlights do not include all the information needed to use pantoprazole sodium delayed - release tablets safely and effectively .", "label": "", "metadata": {}, "score": "61.499092"}
{"text": "There are , however , no adequate and well - controlled studies in pregnant women .Because animal reproduction studies are not always predictive of human response , this drug should be used during pregnancy only if clearly needed [ see Nonclinical Toxicology ( 13.2 ) ] . 8.3", "label": "", "metadata": {}, "score": "61.62671"}
{"text": "The following adverse reactions have been identified during postapproval use of PROTONIX .Because these reactions are reported voluntarily from a population of uncertain size , it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure .", "label": "", "metadata": {}, "score": "61.64379"}
{"text": "Do not use pantoprazole sodium delayed - release tablets for a condition for which it was not prescribed .Do not give pantoprazole sodium delayed - release tablets to other people , even if they have the same symptoms you have .", "label": "", "metadata": {}, "score": "61.67981"}
{"text": "The binding to the ( H + , K + ) -ATPase results in a duration of antisecretory effect that persists longer than 24 hours for all doses tested ( 20 mg to 120 mg ) .", "label": "", "metadata": {}, "score": "61.721725"}
{"text": "The binding to the ( H + , K + ) -ATPase results in a duration of antisecretory effect that persists longer than 24 hours for all doses tested ( 20 mg to 120 mg ) .", "label": "", "metadata": {}, "score": "61.721725"}
{"text": "You may report side effects to the FDA at 1 - 800-FDA-1088 .How should I store Pantoprazole ?Store Pantoprazole at room temperature between 59 \u00b0 to 86 \u00b0 F ( 15 \u00b0 to 30 \u00b0 C ) .", "label": "", "metadata": {}, "score": "61.803932"}
{"text": "A random and at 18-month effect linear regression model was performed to assess differences .Results .Thirty patients completed the study ; indeed , the small sample size and loss to followup were one of the major limitations to this study .", "label": "", "metadata": {}, "score": "61.894623"}
{"text": "Our study provides supportive evidence that combination therapy of low - dose cinacalcet and calcitriol was effective to treat moderate and severe UHPT .Furthermore , our results demonstrated that low - dose cinacalcet as an add - on therapy to standard treatment including calcitriol and phosphate binders improved goal attainment of CKD - mineral bone disease over low - dose calcitriol alone .", "label": "", "metadata": {}, "score": "61.903595"}
{"text": "The six patients undergoingthe showed at 6 months a not significant decrease in the are relativelyfrequent .patients of our conventionaltreatment mean serum levels of iPTH and a not significant increase in the mean serum levels of Ca , P and Ca?P product , when compared with the baseline values .", "label": "", "metadata": {}, "score": "61.98388"}
{"text": "For both , the average daily dose increased slowly with time .Use of magnesium or aluminium - containing binders was negligible .Trends in selected medication use .", "label": "", "metadata": {}, "score": "61.991135"}
{"text": "The authors declare no conflict of interest .References .Kidney Int .[ Google Scholar ] [ CrossRef ] .Pitts , T.O. ; Piraino , B.H. ; Mitro , R. ; Chen , T.C. ; Segre , G.V. ; Greenberg , A. ; Puschett , J.B. Hyperparathyroidism and 1,25-dihydroxyvitamin D deficiency in mild , moderate , and severe renal failure .", "label": "", "metadata": {}, "score": "62.01283"}
{"text": "13 , no . 1 , pp .134 - 141 , 2004 .View at Google Scholar \u00b7 View at Scopus . A. Galassi , D. M. Spiegel , A. Bellasi , G. A. Block , and P. Raggi , \" Accelerated vascular calcification and relative hypoparathyroidism in incident haemodialysis diabetic patients receiving calcium binders , \" Nephrology Dialysis Transplantation , vol .", "label": "", "metadata": {}, "score": "62.03248"}
{"text": "Serum levels of albumin , iPTH , calcium ( Ca ) , phosphate ( P ) and alkaline phosphatase were deter- mined monthly .The treatment group included four cases of nodular hyperplasia and two cases of car- cinoma of parathyroid glands , whereas the control group included four cases of nodular hyperplasia and two cases of diffuse hyperplasia .", "label": "", "metadata": {}, "score": "62.062386"}
{"text": "Information describing use in pediatric patients ages five years through 16 years old with erosive esophagitis associated with GERD is approved for Wyeth Pharmaceuticals Inc. 's pantoprazole sodium delayed - release tablets .", "label": "", "metadata": {}, "score": "62.109756"}
{"text": "5.6 Clostridium difficile associated diarrhea .Published observational studies suggest that PPI therapy like PROTONIX may be associated with an increased risk of Clostridium difficile associated diarrhea , especially in hospitalized patients .", "label": "", "metadata": {}, "score": "62.13631"}
{"text": "[ Google Scholar ] [ CrossRef ] .Teng , M. ; Wolf , M. ; Ofsthun , M.N. ; Lazarus , J.M. ; Hern\u00e1n , M.A. ; Camargo , C.A. , Jr. ; Thadhani , R. Activated injectable vitamin D and hemodialysis survival : A historical cohort study .", "label": "", "metadata": {}, "score": "62.28186"}
{"text": "Although serum half - life values increased to 7 - 9 hours and AUC values increased by 5- to 7-fold in hepatic - impaired patients , these increases were no greater than those observed in CYP2C19 poor metabolizers , where no dosage adjustment is warranted .", "label": "", "metadata": {}, "score": "62.341946"}
{"text": "This effect leads to inhibition of both basal and stimulated gastric acid secretion , irrespective of the stimulus .The binding to the ( H + , K + ) -ATPase results in a duration of antisecretory effect that persists longer than 24 hours for all doses tested ( 20 mg to 120 mg ) .", "label": "", "metadata": {}, "score": "62.364494"}
{"text": "Warfarin ( Coumadin , Athrombin - K , Jantoven , Panwarfin ) .Clopidogrel ( Plavix ) .Ketoconazole ( Nizoral ) .Atazanavir ( Reyataz ) , .", "label": "", "metadata": {}, "score": "62.36657"}
{"text": "At the end of study , decrease in calcitriol usage and mean weekly dosage of intravenous calcitriol was observed in the VitD group .Discussion .", "label": "", "metadata": {}, "score": "62.493862"}
{"text": "Conclusions .A reduction in rates of parathyroidectomy was found after January 2006 , corresponding to cinacalcet availability .However , decreased rates may be due to other factors occurring simultaneously with cinacalcet introduction and further studies are needed to confirm these findings .", "label": "", "metadata": {}, "score": "62.514416"}
{"text": "Study 1 was a multicenter , double - blind , placebo - controlled , study of the pharmacodynamic effects of PROTONIX I.V. for Injection and oral PROTONIX .", "label": "", "metadata": {}, "score": "62.643185"}
{"text": "Iron supplements .Ampicillin antibiotics Ask your doctor if you are not sure if any of your medicines are the kind listed above .How should I take pantoprazole sodium delayed - release tablets ?", "label": "", "metadata": {}, "score": "62.667572"}
{"text": "Researchers want to see if cinacalcet can help blood phosphorus and decrease the amount of phosphorus supplements that people need to take .Objectives : . -", "label": "", "metadata": {}, "score": "62.711967"}
{"text": "A mean of 1.3 \u00b1 0.8 ethanol injections was performed .Nodular volume was 1.5 \u00b1 1.7 cm(3 ) , and 2.8 \u00b1 2.8 cm(3 ) of ethanol was injected per patient .", "label": "", "metadata": {}, "score": "62.839207"}
{"text": "Tell your doctor about all of the medicines you take , including prescription and non - prescription drugs , vitamins and herbal supplements .Pantoprazole sodium delayed - release tablets may affect how other medicines work , and other medicines may affect how pantoprazole sodium delayed - release tablet works .", "label": "", "metadata": {}, "score": "62.84864"}
{"text": "The calcimimetic AMG 073 reduces parathyroid hormone and calciumxpho- sphorus in secondary hyperparathyroidism .Kidney Int 2003 ; 63 : 248 - 254 14 .Basile C , Lomonte C , Vernaglione L et al .", "label": "", "metadata": {}, "score": "62.867203"}
{"text": "and aluminium - based compounds ) on patient - level outcomes .The largest of these studies , the Dialysis Clinical Outcomes Revisited ( DCOR ) study , [ 29 ] randomized 2103 prevalent CKD stage 5D patients to either sevelamer HCl or a calcium - based phosphate binder ( 70 % calcium acetate or 30 % calcium carbonate ) .", "label": "", "metadata": {}, "score": "62.877605"}
{"text": "Rare reports of cyanocobalamin deficiency occurring with acid - suppressing therapy have been reported in the literature .This diagnosis should be considered if clinical symptoms consistent with cyanocobalamin deficiency are observed .", "label": "", "metadata": {}, "score": "62.93238"}
{"text": "6 , pp .386 - 391 , 2007 .View at Google Scholar .S. Fan , C. Ross , S. Mitra et al . , \" A randomized , crossover design study of sevelamer carbonate powder and sevelamer hydrochloride tablets in chronic kidney disease patients on haemodialysis , \" Nephrology Dialysis Transplantation , vol .", "label": "", "metadata": {}, "score": "63.013096"}
{"text": "It may harm them .This Patient Information leaflet provides a summary of the most important information about Pantoprazole .For more information , ask your doctor .", "label": "", "metadata": {}, "score": "63.039673"}
{"text": "Pantoprazole metabolism is independent of the route of oral administration .The main metabolic pathway is demethylation , by CYP2C19 , with subsequent sulfation ; other metabolic pathways include oxidation by CYP3A4 .", "label": "", "metadata": {}, "score": "63.250263"}
{"text": "6.1 Clinical Trial Experience .Because clinical trials are conducted under widely varying conditions , adverse reaction rates observed in the clinical trials of a drug can not be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice .", "label": "", "metadata": {}, "score": "63.3105"}
{"text": "6.1 Clinical Trials Experience .Because clinical trials are conducted under widely varying conditions , adverse reaction rates observed in the clinical trials of a drug can not be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice .", "label": "", "metadata": {}, "score": "63.331245"}
{"text": "Srinivas TR , Schold JD , Womer KL et al .Improvement in hypercalcemia with cinacalcet after kidney transplantation .Cl J Am Soc Nephrol 2006 ; 1 : 323 - 326 21 .", "label": "", "metadata": {}, "score": "63.459312"}
{"text": "114 , pp .S26 - 33 , 2009 .View at Google Scholar \u00b7 View at Scopus . K. Caglar , M. I. Yilmaz , M. Saglam et al . , \" Short - term treatment with sevelamer increases serum fetuin - A concentration and improves endothelial dysfunction in chronic kidney disease stage 4 patients , \" Clinical Journal of the American Society of Nephrology , vol .", "label": "", "metadata": {}, "score": "63.501564"}
{"text": "It is not surprising that only 61 % subjects in the VitD group received calcitriol treatment at the end of 6 months .The intermittent interruption and decreased dosage of calcitriol during the treatment period contributed to only modest reduction in iPTH levels with a lesser proportion able to achieve the K / DOQI - recommended biochemical targets in the VitD group .", "label": "", "metadata": {}, "score": "63.540283"}
{"text": "PROTONIX I.V. for Injection had an onset of antisecretory activity within 15 to 30 minutes of administration .Doses of 20 to 80 mg of PROTONIX I.V. for Injection substantially reduced the 24-hour cumulative PSAO in a dose - dependent manner , despite a short plasma elimination half - life .", "label": "", "metadata": {}, "score": "63.564205"}
{"text": "It does however seem feasible that this product may possess a similar efficacy in the treatment of vascular calcifications in patients at all stages of CKD [ 50 ] .", "label": "", "metadata": {}, "score": "63.688282"}
{"text": "Pantoprazole metabolism is independent of the route of administration ( intravenous or oral ) .The main metabolic pathway is demethylation , by CYP2C19 , with subsequent sulfation ; other metabolic pathways include oxidation by CYP3A4 .", "label": "", "metadata": {}, "score": "63.79751"}
{"text": "Successful treatment of hypercalcemia with cinacalcet in renal transplant recipients with persistent hyperparathyroidism .Nephrol Dial Transplant 2005 ; 20 : 1315 - 1319 19 .", "label": "", "metadata": {}, "score": "63.932632"}
{"text": "The high PTH levels lead to uremic bone disease .Cinacalcet HCL is effective in lowering the elevated PTH levels in chronic renal failure patients .", "label": "", "metadata": {}, "score": "64.10263"}
{"text": "Nephrol .Dial .Transplant .[ Google Scholar ] [ CrossRef ] .Palmer , S.C. ; McGregor , D.O. ; Macaskill , P. ; Craig , J.C. ; Elder , G.J. ; Strippoli , G.F. Meta - Analysis : Vitamin D compounds in chronic kidney disease .", "label": "", "metadata": {}, "score": "64.120926"}
{"text": "Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated .Patients at risk for osteoporosis - related fractures should be managed according to established treatment guidelines [ see Dosage and Administration ( 2 ) and Adverse Reactions ( 6 ) ] . 5.8 Hepatic Effects .", "label": "", "metadata": {}, "score": "64.18851"}
{"text": "Poor metabolizers exhibited approximately 10-fold lower apparent oral clearance compared to extensive metabolizers .For known pediatric poor metabolizers , a dose reduction should be considered .", "label": "", "metadata": {}, "score": "64.36329"}
{"text": "However , the effects of magnesium on vascular calcification and bone mineral density have not been studied prospectively .Magnesium carbonate / calcium carbonate administered as the principal phosphate binder for a period of 18 months and changes in CAC and V - BMD were measured at baseline , 6 , 12 , and 18 months .", "label": "", "metadata": {}, "score": "64.40867"}
{"text": "Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated .Patients at risk for osteoporosis - related fractures should be managed according to established treatment guidelines [ see Dosage and Administration ( 2 ) and Adverse Reactions ( 6.2 ) ] .", "label": "", "metadata": {}, "score": "64.42158"}
{"text": "Pantoprazole causes long - lasting inhibition of gastric acid secretion .Therefore , pantoprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability ( e.g. , ketoconazole , ampicillin esters , and iron salts ) .", "label": "", "metadata": {}, "score": "64.43591"}
{"text": "Hypersensitivity reactions may include anaphylaxis , anaphylactic shock , angioedema , bronchospasm , acute interstitial nephritis , and urticaria [ see Adverse Reactions ( 6 ) ] .", "label": "", "metadata": {}, "score": "64.47168"}
{"text": "The latter does not appear to be able to control these forms ; furthermore , the risk of inducing hypercalcaemia and/or hyperphosphataemia with theconventionaltreatment unavoidable therapeutic discontinuity , which repre- sents a further limit to the efficacy of the conventional treatment .", "label": "", "metadata": {}, "score": "64.522194"}
{"text": "14.2 Pathological Hypersecretion Associated with Zollinger - Ellison Syndrome .Two studies measured the pharmacodynamic effects of 6 day treatment with PROTONIX I.V. for Injection in patients with Zollinger - Ellison Syndrome ( with and without multiple endocrine neoplasia type I ) .", "label": "", "metadata": {}, "score": "64.550064"}
{"text": "Furthermore , a decrease in the expression of the nitrotyrosine marker of inflammatory stress by atherosclerotic plaques in the aorta and stabilization of the plaques , a decrease in CRP , and a reduced gastrointestinal absorption of several uremic toxins have also been reported [ 46 ] .", "label": "", "metadata": {}, "score": "64.65584"}
{"text": "A case report reviewed 12 patients with parathyroid carcinoma who were receiving mainte- nance haemodialysis [ 24].All demonstrated hyper- plasia of other parathyroid glands .", "label": "", "metadata": {}, "score": "64.66592"}
{"text": "Cinacalcet HCL : a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease .J Ren Nutr .Yu HT .Progression of chronic renal failure .", "label": "", "metadata": {}, "score": "64.691025"}
{"text": "According to Amgen data , cinacalet claims were estimated at 241 in 2005 and 385 in 2006 ( Amgen internal data ) .Assuming monthly claims ( 12 claims per patients per year ) , it can be estimated that 20 patients received cinacalcet through private insurance companies in 2005 and 32 patients in 2006 .", "label": "", "metadata": {}, "score": "64.74044"}
{"text": "The average parathyroidectomy rate before cinacalcet availability was 11.4 /1000 person - years , and 3.6 /1000 person - years after cinacalcet public formulary listing .", "label": "", "metadata": {}, "score": "64.91332"}
{"text": "Hypomagnesemia has been reported rarely with prolonged treatment with PPIs ( 5.9 ) .1.2 Pathological Hypersecretion Including Zollinger - Ellison Syndrome . 2 DOSAGE AND ADMINISTRATION .", "label": "", "metadata": {}, "score": "64.959854"}
{"text": "There is a modest increase in pantoprazole AUC and Cmax in women compared to men .However , weight - normalized clearance values are similar in women and men .", "label": "", "metadata": {}, "score": "65.03937"}
{"text": "6 , pp .683 - 692 , 2010 .View at Google Scholar .C. D. Chue , J. N. Townend , R. P. Steeds , and C. J. Ferro , \" Evaluating the effects of sevelamer carbonate on cardiovascular structure and function in chronic renal impairment in Birmingham : the CRIB - PHOS randomised controlled trial , \" Trials , vol .", "label": "", "metadata": {}, "score": "65.103874"}
{"text": "It is not known if Pantoprazole will harm your unborn baby .Talk to your doctor if you are pregnant or plan to become pregnant .", "label": "", "metadata": {}, "score": "65.18855"}
{"text": "Take Pantoprazole exactly as prescribed by your doctor .Do not change your dose or stop Pantoprazole without talking to your doctor .If you forget to take a dose of Pantoprazole , take it as soon as you remember .", "label": "", "metadata": {}, "score": "65.36739"}
{"text": "Analysis of longitudinal within - group continuous data was assessed by paired tests .Ethical Issues .The study was approved by the Institutional Review Board of Chang - Gung Memorial Hospital ( IRB number : 101 - 4851B ) .", "label": "", "metadata": {}, "score": "65.41737"}
{"text": "We use to treat all PTx patients , who represent a very selected category , with a Ca concentration in the dialysate of 6.0mg / dl at variance with Ca concentra- tion of 5.0mg / dl recommended by the NKF / K - DOQI guidelines [ 9].", "label": "", "metadata": {}, "score": "65.500534"}
{"text": "Moe SM , Chertow GM , Coburn JW et al .Achieving NKF - K/ DOQI bone metabolism and disease treatment goals with cinacalcet HCl .", "label": "", "metadata": {}, "score": "65.593704"}
{"text": "There have been reports of false positive urine screening tests for tetrahydrocannabinol ( THC ) in patients receiving proton pump inhibitors .An alternative confirmatory method should be considered to verify positive results . 7.6 Methotrexate .", "label": "", "metadata": {}, "score": "65.65431"}
{"text": "307 - 315 , 2010 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at PubMed \u00b7 View at Scopus .M. D. Arenas , P. Rebollo , T. Malek et al . , \" A comparative study of 2 new phosphate binders ( sevelamer and lanthanum carbonate ) in routine clinical practice , \" Journal of Nephrology , vol .", "label": "", "metadata": {}, "score": "65.70198"}
{"text": "The tendency is to reduce calcium intake both through dialysis and by administration of non - calcium phosphate binders that have proved effective in controlling hyperphosphatemia but which also feature pharmacological characteristics capable of producing a direct decrease in calcifications to the vascular endothelium .", "label": "", "metadata": {}, "score": "65.76674"}
{"text": "Pantoprazole sodium delayed - release tablets is not for children under 5 years old .Who should not take pantoprazole sodium delayed - release tablets ?", "label": "", "metadata": {}, "score": "65.80966"}
{"text": "Kidney Int .2009 , 76 , S1-S130 .Clin .Nephrol .[ Google Scholar ] .Martin , K.J. ; Gonz\u00e1lez , E.A. ; Gellens , M. ; Hamm , L.L. ; Abboud , H. ; Lindberg , J. 19-Nor-1-alpha-25-dihydroxyvitamin D2 ( paricalcitol ) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis .", "label": "", "metadata": {}, "score": "66.35254"}
{"text": "Pantoprazole may pass into your milk .Talk with your doctor about the best way to feed your baby if you take Pantoprazole .Tell your doctor about all of the medicines you take , including prescription and non - prescription drugs , vitamins and herbal supplements .", "label": "", "metadata": {}, "score": "66.4198"}
{"text": "Experimental Section .Study Population .In the retrospective study , adult uremic patients those have been receiving chronic dialysis therapy for at least 3 months in our hospital were eligible for screening .", "label": "", "metadata": {}, "score": "66.56431"}
{"text": "The dosage of PROTONIX I.V. for Injection in patients with pathological hypersecretory conditions including Zollinger - Ellison Syndrome varies with individual patients .The recommended adult dosage is 80 mg intravenously every 12 hours .", "label": "", "metadata": {}, "score": "66.63214"}
{"text": "Abstract .Background .Recent trends in parathyroidectomy rates are not known .Our objective was to investigate the trend in parathyroidectomy rates between 2001 and 2010 , and to evaluate if the availability and reimbursement of cinacalcet modified that trend .", "label": "", "metadata": {}, "score": "66.647354"}
{"text": "In other words , rates did not appear to increase or decrease over time except at the intervention point .Results for the ARIMA and Poisson analyses were similar when time periods not covered by the drug plan were excluded , except that June 2005 became statistically significant in addition to January 2006 .", "label": "", "metadata": {}, "score": "66.69882"}
{"text": "Nephrol .Dial .Transplant .[ Google Scholar ] .Rothe , H.M. ; Shapiro , W.B. ; Sun , W.Y. ; Chou , S.Y. Calcium - Sensing receptor gene polymorphism Arg990Gly and its possible effect on response to cinacalcet HCl .", "label": "", "metadata": {}, "score": "66.75597"}
{"text": "General Information .Medicines are sometimes prescribed for purposes other than those listed in the Patient Information leaflet .Do not use Pantoprazole for a condition for which it was not prescribed .", "label": "", "metadata": {}, "score": "66.7901"}
{"text": "Acute interstitial nephritis has been observed in patients taking PPIs .PPI therapy may be associated with increased risk of Clostridium difficile associated diarrhea ( 5.6 ) .", "label": "", "metadata": {}, "score": "66.88469"}
{"text": "Safety of treatment beyond 8 weeks in pediatric patients has not been established .Pediatric indication and usage information in pediatric patients ages five years and older with erosive esophagitis associated with GERD is approved for Wyeth Pharmaceuticals Inc. 's pantoprazole sodium delayed - release tablets .", "label": "", "metadata": {}, "score": "66.93152"}
{"text": "Safety of treatment beyond 8 weeks in pediatric patients has not been established .Pediatric indication and usage information in pediatric patients ages five years and older with erosive esophagitis associated with GERD is approved for Wyeth Pharmaceuticals Inc. 's pantoprazole sodium delayed - release tablets .", "label": "", "metadata": {}, "score": "66.93152"}
{"text": "What should I tell my doctor before taking pantoprazole sodium delayed - release tablets ?Before you take pantoprazole sodium delayed - release tablets , tell your doctor if you : . have been told that you have low magnesium levels in your blood . are pregnant , think you may be pregnant , or are planning to become pregnant .", "label": "", "metadata": {}, "score": "66.99963"}
{"text": "A total of 81 dialysis patients were enrolled ( 40 subjects in d -Cinacalcet group and 41 subjects in VitD group ) .Demographic data including age , gender , duration on dialysis and biochemical data were reviewed and recorded .", "label": "", "metadata": {}, "score": "67.03749"}
{"text": "The total volume from both vials should be administered intravenously over a period of at least 2 minutes .3 DOSAGE FORMS AND STRENGTHS .4 CONTRAINDICATIONS .", "label": "", "metadata": {}, "score": "67.04671"}
{"text": "61 - 68 , 2008 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at PubMed . S. Fishbane , J. Delmez , W. N. Suki et al . , \" A randomized , parallel , open - label study to compare once - daily sevelamer carbonate powder dosing with thrice - daily sevelamer hydrochloride tablet dosing in CKD patients on hemodialysis , \" American Journal of Kidney Diseases , vol .", "label": "", "metadata": {}, "score": "67.04744"}
{"text": "PubMed View Article .The EVOLVE Trial Investigators : Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis .N Engl J Med 2012 , 367 : 2482 - 2494 .", "label": "", "metadata": {}, "score": "67.083084"}
{"text": "Moe SM , Cunningham J , Bommer J et al .Long - term treatment of secondary hyperparathyroidism with the calcimi- metic cinacalcet HCl .Nephrol Dial Transplant 2005 ; 20 : 2186 - 2193 9 .", "label": "", "metadata": {}, "score": "67.29346"}
{"text": "PROTONIX I.V. for Injection maintained or improved control of gastric acid secretion .In both studies , PROTONIX I.V. for Injection 160 or 240 mg per day in divided doses maintained basal acid secretion below target levels in all patients .", "label": "", "metadata": {}, "score": "67.40175"}
{"text": "What is Pantoprazole ?Pantoprazole is a prescription medicine called a proton pump inhibitor ( PPI ) .Pantoprazole is used in adults for : .", "label": "", "metadata": {}, "score": "67.98744"}
{"text": "Each vial of PROTONIX I.V. for Injection should be reconstituted with 10 mL of 0.9 % Sodium Chloride Injection , USP .The reconstituted solution may be stored for up to 6 hours at room temperature prior to further dilution .", "label": "", "metadata": {}, "score": "68.01488"}
{"text": "Hypomagnesemia , symptomatic and asymptomatic , has been reported rarely in patients treated with PPIs for at least three months , in most cases after a year of therapy .", "label": "", "metadata": {}, "score": "68.02925"}
{"text": "An important point is that , however , two out of these patients were non - responders : we hypothesize that this might be due to the loss of CaSR in parathyroid carcinoma and in part of parathyroid nodular hyperplasia .", "label": "", "metadata": {}, "score": "68.03319"}
{"text": "Metabolic / Nutritional : elevated CK ( creatine kinase ) , generalized edema , elevated triglycerides , liver enzymes elevated .Musculoskeletal : myalgia .Adverse reaction information in pediatric patients with erosive esophagitis associated with GERD is approved for Wyeth Pharmaceuticals Inc. 's pantoprazole sodium delayed - release tablets .", "label": "", "metadata": {}, "score": "68.0877"}
{"text": "Metabolic / Nutritional : elevated CK ( creatine kinase ) , generalized edema , elevated triglycerides , liver enzymes elevated .Musculoskeletal : myalgia .Adverse reaction information in pediatric patients with erosive esophagitis associated with GERD is approved for Wyeth Pharmaceuticals Inc. 's pantoprazole sodium delayed - release tablets .", "label": "", "metadata": {}, "score": "68.0877"}
{"text": "Both the reconstituted solution and the admixed solution do not need to be protected from light .PROTONIX I.V. for Injection should be administered intravenously over a period of approximately 15 minutes at a rate of approximately 7 mL / min .", "label": "", "metadata": {}, "score": "68.18222"}
{"text": "After six months of treatment , a statistically significant reduction in the mean serum levels of iPTH ( from 1388.3 ?461.7 to 435.0 ? 0.6 to 8.3 ? 1.2 to 3.8 ?", "label": "", "metadata": {}, "score": "68.246124"}
{"text": "23 , no .5 , pp .556 - 562 , 2010 .View at Google Scholar .M. Ketteler , M. Rix , S. Fan et al . , \" Efficacy and tolerability of sevelamer carbonate in hyperphosphatemic patients who have chronic kidney disease and are not on dialysis , \" Clinical Journal of the American Society of Nephrology , vol .", "label": "", "metadata": {}, "score": "68.36713"}
{"text": "Because of diverse mechanisms in the pathogenesis of UHPT , the concept of combination therapy of cinacalcet and low - dose vitamin D emerged , and clinicians can now use vitamin D more actively due to lower calcium and phosphorus levels during cinacalcet treatment .", "label": "", "metadata": {}, "score": "68.39833"}
{"text": "Moreover , because the ARIMA model relied on time points and not on patient - level exposure , incomplete ascertainment of exposure does not influence our results .", "label": "", "metadata": {}, "score": "68.45285"}
{"text": "Hypomagnesemia , symptomatic and asymptomatic , has been reported rarely in patients treated with PPIs for at least three months , and in most cases after a year of therapy .", "label": "", "metadata": {}, "score": "68.72339"}
{"text": "76 , supplement 113 , pp .S50-S99 , 2009 .C. Zehnder , J. P. Gutzwiller , and K. Renggli , \" Hemodiafiltration - a new treatment option for hyperphosphatemia in hemodialysis patients , \" Clinical Nephrology , vol .", "label": "", "metadata": {}, "score": "68.79867"}
{"text": "See the end of this leaflet for a complete list of ingredients in pantoprazole sodium delayed - release tablets .allergic to any proton pump inhibitor ( PPI ) .", "label": "", "metadata": {}, "score": "68.8138"}
{"text": "Parathyroidectomy ( PTX ) is primarily reserved for symptomatic patients with elevated parathyroid hormone ( PTH ) levels despite optimal medical therapy .While cinacalcet has been shown in trials to reduce PTH levels [ 2 ] and to lower incidence of PTX [ 3 , 4 ] , it remains unclear how availability of this new drug influenced PTX rate trends in a real - world setting .", "label": "", "metadata": {}, "score": "69.18553"}
{"text": "Please reference the How Supplied section listed above for a description of individual tablets or capsules .This drug product has been received by Aphena Pharma - TN in a manufacturer or distributor packaged configuration and repackaged in full compliance with all applicable cGMP regulations .", "label": "", "metadata": {}, "score": "69.345856"}
{"text": "Study sample .Chronic dialysis was defined as at least 90 days of dialysis , and therefore patients with less than 90 days of follow - up were excluded .", "label": "", "metadata": {}, "score": "69.40548"}
{"text": "Caution should be used when other EDTA containing products are also co - administered intravenously .5.5 Acute Interstitial Nephritis .Acute interstitial nephritis has been observed in patients taking PPIs including PROTONIX I.V. Acute interstitial nephritis may occur at any point during PPI therapy and is generally attributed to an idiopathic hypersensitivity reaction .", "label": "", "metadata": {}, "score": "69.50858"}
{"text": "12.5 Pharmacogenomics .CYP2C19 displays a known genetic polymorphism due to its deficiency in some subpopulations ( e.g. , approximately 3 % of Caucasians and African - Americans and 17 % to 23 % of Asians are poor metabolizers ) .", "label": "", "metadata": {}, "score": "69.545166"}
{"text": "Treating a rare condition called Zollinger - Ellison Syndrome , where the stomach makes more than the normal amount of acid .Information describing use in pediatric patients ages five years through 16 years old with erosive esophagitis associated with GERD is approved for Wyeth Pharmaceuticals Inc. 's pantoprazole sodium delayed - release tablets .", "label": "", "metadata": {}, "score": "69.55524"}
{"text": "29 - 34 , 2007 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .N. D. Toussaint , K. K. Lau , K. R. Polkinghorne , and P. G. Kerr , \" Attenuation of aortic calcification with lanthanum carbonate versus calcium - based phosphate binders in haemodialysis : a pilot randomized controlled trial , \" Nephrology , vol .", "label": "", "metadata": {}, "score": "69.70059"}
{"text": "It therefore indicates that combined therapy may reduce the use of aluminum hydroxide and lower the risk of aluminum toxicity in dialysis patients .Limitations of the Study .", "label": "", "metadata": {}, "score": "69.74459"}
{"text": "Relatively few papers have been published , including an Italian study involving 90 binder - naive Italian patients with CKD stages 3 - 5 who were not receiving dialysis .", "label": "", "metadata": {}, "score": "69.86995"}
{"text": "In a 24-month carcinogenicity study , Fischer 344 rats were treated orally with doses of 5 to 50 mg / kg / day , approximately 1 to 10 times the recommended human dose based on body surface area .", "label": "", "metadata": {}, "score": "70.0009"}
{"text": "In a 24-month carcinogenicity study , Fischer 344 rats were treated orally with doses of 5 to 50 mg / kg / day , approximately 1 to 10 times the recommended human dose based on body surface area .", "label": "", "metadata": {}, "score": "70.0009"}
{"text": "MAO and BAO were determined 24 hours following the last day of study medication .MAO was estimated from a 1 hour continuous collection of gastric contents following subcutaneous injection of 6.0 \u03bcg / kg of pentagastrin to stimulate acid secretion .", "label": "", "metadata": {}, "score": "70.05446"}
{"text": "This combination therapy is associated with improvement in hyperphosphatemia and hypercalcemia .Furthermore , there was a significant decrease in the usage and dosage of aluminum hydroxide in combination therapy at the end of the treatment period .", "label": "", "metadata": {}, "score": "70.07279"}
{"text": "Fasting serum gastrin levels generally remained at approximately 2 to 3 times baseline for up to 4 years of periodic follow - up in clinical trials .", "label": "", "metadata": {}, "score": "70.20776"}
{"text": "Fasting serum gastrin levels generally remained at approximately 2 to 3 times baseline for up to 4 years of periodic follow - up in clinical trials .", "label": "", "metadata": {}, "score": "70.20776"}
{"text": "Because animal reproduction studies are not always predictive of human response , this drug should be used during pregnancy only if clearly needed [ see Nonclinical Toxicology ( 13.2 ) ] . 8.3", "label": "", "metadata": {}, "score": "70.36678"}
{"text": "Because animal reproduction studies are not always predictive of human response , this drug should be used during pregnancy only if clearly needed [ see Nonclinical Toxicology ( 13.2 ) ] . 8.3", "label": "", "metadata": {}, "score": "70.36678"}
{"text": "If you have high blood pressure , hyperlipidemia , or diabetes , medications will likely be ordered to control these conditions .Leakage of protein from the urine is treated with two drugs used in the treatment of high blood pressure : angiotensin - converting enzyme ( ACE ) inhibitors and angiotensin receptor blockers ( ARBs ) .", "label": "", "metadata": {}, "score": "70.42042"}
{"text": "Few studies have evaluated trends in PTX rates , and only one has reported rates after the release of the KDOQI clinical practice guidelines in 2003 , and none have included patients well beyond introduction of calcimetics [ 5 - 8 ] .", "label": "", "metadata": {}, "score": "70.56244"}
{"text": "cramps or muscle aches . spasm of the voice box .Your doctor may check the level of magnesium in your body before you start taking pantoprazole sodium delayed - release tablets or during treatment if you will be taking pantoprazole sodium delayed - release tablets for a long period of time .", "label": "", "metadata": {}, "score": "70.57227"}
{"text": "Finally , Table 3 shows individual results as far as biochemistry ( serum Ca , P and iPTH ) is concerned at three time - points ( at the baseline , at three and six months ) .", "label": "", "metadata": {}, "score": "70.66205"}
{"text": "However , this study was limited to 2007 ( less than three years after cinacalcet marketing ) [ 5 ] .In addition , the effect of formulary listing of cinacalcet for reimbursement on PTX rates has not been studied .", "label": "", "metadata": {}, "score": "70.73817"}
{"text": "The calcimimetic cinacalcet normalizes serum calcium in renal transplantpatientswith Nephrol Dial Transplant 2005 ; 20 : 1311 - 1314 multicenterstudy .J Am Soc cinacalcetHClon persistenthyperparathyroidism .", "label": "", "metadata": {}, "score": "70.74025"}
{"text": "There is insufficient evidence that any specific phosphate binder significantly impacts patient - level outcomes .Thus , the choice of phosphate binder should be selected on an individual basis .", "label": "", "metadata": {}, "score": "70.87169"}
{"text": "Secondary , retrospective study may not include all patients enrolled initially .Patients who can not tolerate treatment or who withdrew because of any other reasons will be excluded .", "label": "", "metadata": {}, "score": "70.9211"}
{"text": "Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated .5.7 Bone Fracture .Several published observational studies suggest that proton pump inhibitor ( PPI ) therapy may be associated with an increased risk for osteoporosis - related fractures of the hip , wrist , or spine .", "label": "", "metadata": {}, "score": "71.11244"}
{"text": "Baseline Characteristics between Different Treatment Groups ( Table 1 ) .Table 1 shows the baseline demographic and laboratory parameters of enrolled patients .Among 81 subjects , approximately three - quarters had severe UHPT ( defined as having an iPTH level greater than 800 pg / mL ) and one - quarter of the patients had moderate UHPT ( defined as iPTH between 500 and 800 pg / mL ) .", "label": "", "metadata": {}, "score": "71.13253"}
{"text": "PubMed View Article .Kestenbaum B , Seliger SL , Gillen DL , Wasse H , Young B , Sherrard DJ , Weiss NS , Stehman - Breen CO : Parathyroidectomy rates among United States dialysis patients : 1990 - 1999 .", "label": "", "metadata": {}, "score": "71.15688"}
{"text": "As with most retrospective studies using dispensed medications , there is uncertainty with patient compliance .In addition , intravenous vitamin D analogue claims are not captured within the RAMQ database , since vitamin D analogues are dispensed by the dialysis unit and a claim would not be submitted by the patient to the RAMQ .", "label": "", "metadata": {}, "score": "71.256165"}
{"text": "Erosive esophagitis healing rates in the 221 women treated with Pantoprazole Sodium Delayed - Release Tablets in US clinical trials were similar to those found in men .", "label": "", "metadata": {}, "score": "71.4357"}
{"text": "However , it is speculated that wider availability of cinacalcet through reimbursement in Qu\u00e9bec may be a factor .The higher PTX rates observed here among prevalent and younger patients are consistent with previous studies and with the physiopathology of secondary hyperparathyroidism [ 5 , 20 ] .", "label": "", "metadata": {}, "score": "71.67544"}
{"text": "Serum alkaline phosphatase also declined ( 561.8 + /- 169.6 U / L pretreatment to 390.3 + /- 110.3 U / L posttreatment pg / ml ) .", "label": "", "metadata": {}, "score": "71.72209"}
{"text": "There was no significant difference in symptom relief between PROTONIX I.V. and oral PROTONIX therapy within the first 5 days .A repeat endoscopy after 8 weeks of treatment revealed that 20 out of 23 ( 87 % ) of the PROTONIX I.V. plus oral PROTONIX patients and 19 out of 22 ( 86 % ) of the oral PROTONIX patients had endoscopically proven healing of their esophageal lesions .", "label": "", "metadata": {}, "score": "71.84506"}
{"text": "16 HOW SUPPLIED / STORAGE AND HANDLING .Pantoprazole Sodium Delayed - Release Tablets , USP are supplied as 40 mg white , oval biconvex delayed - release tablets imprinted in black ink with \" KU \" and \" 181 \" on one side and are available as follows : .", "label": "", "metadata": {}, "score": "71.85953"}
{"text": "In 2003 , KDOQI guidelines [ 19 ] recommended a maximum dose of 1500 mg / day of elemental calcium , which was significantly lower than the usual practice .", "label": "", "metadata": {}, "score": "72.0043"}
{"text": "Use PROTONIX I.V. with caution in transplant patients receiving MMF [ see Clinical Pharmacology ( 12.3 ) ] . 7.5 False Positive Urine Tests for THC .", "label": "", "metadata": {}, "score": "72.006256"}
{"text": "[ See USP Controlled Room Temperature].Keep pantoprazole sodium delayed - release tablets and all medicines out of the reach of children .General Information .", "label": "", "metadata": {}, "score": "72.060486"}
{"text": "If you need to use sodium bicarbonate , you should review your dietary sodium intake with your physician or dietician .This medication will increase the sodium in your diet .", "label": "", "metadata": {}, "score": "72.07765"}
{"text": "Inform patients that the most frequently occurring adverse reactions in US clinical trials for adults are headache , diarrhea , nausea , abdominal pain , vomiting , flatulence , dizziness , and arthralgia .", "label": "", "metadata": {}, "score": "72.0938"}
{"text": "In the forestomach , treatment at 50 and 200 mg / kg / day ( about 10 and 40 times the recommended human dose on a body surface area basis ) produced benign squamous cell papillomas and malignant squamous cell carcinomas .", "label": "", "metadata": {}, "score": "72.12534"}
{"text": "In the forestomach , treatment at 50 and 200 mg / kg / day ( about 10 and 40 times the recommended human dose on a body surface area basis ) produced benign squamous cell papillomas and malignant squamous cell carcinomas .", "label": "", "metadata": {}, "score": "72.12534"}
{"text": "There have been postmarketing reports of increased INR and prothrombin time in patients receiving proton pump inhibitors , including PROTONIX , and warfarin concomitantly [ see Drug Interactions ( 7.2 ) ] .", "label": "", "metadata": {}, "score": "72.128426"}
{"text": "Almost half of all patients ( 49 % ) died during follow - up and 15 % were transplanted .As shown in Table 1 , patient age increased with time , while proportions of incident patients and of patients on peritoneal dialysis decreased with time .", "label": "", "metadata": {}, "score": "72.173584"}
{"text": "In clinical studies of Zollinger - Ellison Syndrome , adverse reactions reported in 35 patients taking PROTONIX 80 mg / day to 240 mg / day for up to 2 years were similar to those reported in adult patients with GERD . 6.2", "label": "", "metadata": {}, "score": "72.24328"}
{"text": "Kazama JJ , Sato F , Omori K et al .Pretreatment serum FGF-23 levels predict the efficacy of calcitriol therapy in dialysis patients .Kidney Int 2005 ; 67 : 1120 - 1125 17 .", "label": "", "metadata": {}, "score": "72.4548"}
{"text": "RAMQ codes for PTX did not change during the study period .If any percutaneous ethanol ablation procedures of the parathyroid were carried out , these would not be captured , as there is no specific code for this new technique .", "label": "", "metadata": {}, "score": "72.59753"}
{"text": "See full prescribing information for PROTONIX I.V. PROTONIX \u00ae I.V. ( pantoprazole sodium ) for injection , for intravenous use Initial U.S. approval : 2000 .", "label": "", "metadata": {}, "score": "72.60463"}
{"text": "Parathyromatosis and the challenge of treatment .Am J Kidney Dis 2006 ; 48 : 502 - 505 22 .Colloton M , Shatzen E , Miller G et al .", "label": "", "metadata": {}, "score": "72.81546"}
{"text": "In the liver , treatment at 0.5 to 200 mg / kg / day produced dose - related increases in the incidences of hepatocellular adenomas and carcinomas .", "label": "", "metadata": {}, "score": "72.98339"}
{"text": "In the liver , treatment at 0.5 to 200 mg / kg / day produced dose - related increases in the incidences of hepatocellular adenomas and carcinomas .", "label": "", "metadata": {}, "score": "72.98339"}
{"text": "The aim of the present review is not to illustrate the specific actions produced by calcium - based binders and other drugs , including calcimimetic agents , but rather to focus on the direct and indirect mechanism of action of non - calcium phosphate binders .", "label": "", "metadata": {}, "score": "73.012245"}
{"text": "These medications are sometimes referred to as water pills .Diuretics may be taken by mouth or , in some cases , by injection .Possible side effects include : .", "label": "", "metadata": {}, "score": "73.05188"}
{"text": "5.2 Atrophic Gastritis .5.3 Cyanocobalamin ( Vitamin B-12 ) Deficiency .Generally , daily treatment with any acid - suppressing medications over a long period of time ( e.g. , longer than 3 years ) may lead to malabsorption of cyanocobalamin ( Vitamin B-12 ) caused by hypo- or achlorhydria .", "label": "", "metadata": {}, "score": "73.08451"}
{"text": "Poor metabolizers exhibited approximately 10-fold lower apparent oral clearance compared to extensive metabolizers .13 NONCLINICAL TOXICOLOGY .13.1 Carcinogenesis , Mutagenesis , Impairment of Fertility .", "label": "", "metadata": {}, "score": "73.15172"}
{"text": "Possible side effects include : .Nausea .Diarrhea .Upset stomach .Recombinant Human Erythropoietin ( Epoetin Alfa ) .Common names include : .", "label": "", "metadata": {}, "score": "73.564865"}
{"text": "Forty - five HD patients were randomized to either LC or calcium carbonate .The primary outcome of changes to aortic VC after 18 months included superficial femoral artery ( SFA ) VC , bone mineral density ( BMD ) of lumbar spine , and serum markers of mineral metabolism .", "label": "", "metadata": {}, "score": "73.64711"}
{"text": "View at Publisher \u00b7 View at Google Scholar \u00b7 View at PubMed .M. Cozzolino and D. Brancaccio , \" Clinical consequences and novel therapy of hyperphosphatemia : lanthanum carbonate for dialysis patients , \" Recent Patents on Cardiovascular Drug Discovery , vol .", "label": "", "metadata": {}, "score": "73.66353"}
{"text": "The admixed solution may be stored at room temperature and must be used within 24 hours from the time of initial reconstitution .Both the reconstituted solution and the admixed solution do not need to be protected from light .", "label": "", "metadata": {}, "score": "73.68591"}
{"text": "Rodriguez M , Canalejo A , Garfia B , Aguilera E , Almaden Y. Pathogenesis of refractory secondary hyperparathyroidism .Kidney Int 2002 ; 61 [ Suppl 80 ] : S155-S160 3 .", "label": "", "metadata": {}, "score": "73.70895"}
{"text": "Constipation .Loss of appetite .Slow heart rate .Special Considerations .Whenever you are taking a prescription medication , take the following precautions : .", "label": "", "metadata": {}, "score": "73.868385"}
{"text": "12 , pp .3794 - 3799 , 2009 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at PubMed .V. M. Brandenburg , W. Jahnen - Dechent , and M. Ketteler , \" Sevelamer and the bone - vascular axis in chronic kidney disease : bone turnover , inflammation , and calcification regulation , \" Kidney International .", "label": "", "metadata": {}, "score": "73.87782"}
{"text": "Subsequently , papers relating to a total of 9 randomized trials or featuring an effective study design were selected .All studies had focused on the use of non - calcium phosphate binders as a therapeutic option aimed at reducing nonbone , and prevalently vascular , calcifications in a population of 879 patients .", "label": "", "metadata": {}, "score": "73.99686"}
{"text": "One of the possible explanations is genetic variation of CaSR , such as polymorphism , for the diverse response of cinacalcet .[28 ] .", "label": "", "metadata": {}, "score": "74.14398"}
{"text": "This diagnosis should be considered if clinical symptoms consistent with cyanocobalamin deficiency are observed .5.4 Bone Fracture .Several published observational studies suggest that proton pump inhibitor ( PPI ) therapy may be associated with an increased risk for osteoporosis - related fractures of the hip , wrist , or spine .", "label": "", "metadata": {}, "score": "74.34723"}
{"text": "290 - 298 , 2011 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at PubMed .M. Wei , K. Esbaei , J. Bargman , and D. G. Oreopoulos , \" Relationship between serum magnesium , parathyroid hormone , and vascular calcification in patients on dialysis : a literature review , \" Peritoneal Dialysis International , vol .", "label": "", "metadata": {}, "score": "74.43172"}
{"text": "Preliminary Communication Cinacalcet is effective in relapses of secondary hyperparathyroidism after parathyroidectomy Carlo Lomonte , Maurizio Antonelli , Nicola Losurdo , Giovanni Marchio , Bernardo Giammaria and Carlo Basile Division of Nephrology , Miulli General Hospital , Acquaviva delle Fonti , Italy Abstract Background .", "label": "", "metadata": {}, "score": "74.516426"}
{"text": "152 - 159 , 1999 .View at Google Scholar \u00b7 View at Scopus .L. A. Pedrini , V. De Cristofaro , M. Comelli , et al . , \" Long - term effects of high - efficiency on - line haemodiafiltration on uraemic toxicity .", "label": "", "metadata": {}, "score": "74.52615"}
{"text": "However , cinacalcet was not reimbursed via the provincial formulary until June 2006 , and was only reimbursed by private insurance companies for a few patients who had private insurances coverage ( less than 22 % annually ) .", "label": "", "metadata": {}, "score": "74.575"}
{"text": "PubMed View Article .Block GA , Hulbert - Shearon TE , Levin NW , Port FK : Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients : a national study .", "label": "", "metadata": {}, "score": "74.642136"}
{"text": "Some drugs can be dangerous when mixed .Talk to a doctor or pharmacist if you are taking more than one drug .This includes over - the - counter medication and herb or dietary supplements .", "label": "", "metadata": {}, "score": "74.6519"}
{"text": "Serum concentrations of immunoassay calciumlevels\u00fe[(4.0 ?Page 3 .Statistical analyses The distribution of the data was studied by means of the Kolmogorov - Smirnov test : all of them were non - normally distributed .", "label": "", "metadata": {}, "score": "74.70894"}
{"text": "PubMed View Article .Malberti F , Marcelli D , Conte F , Limido A , Spotti D , Locatelli F : Parathyroidectomy in patients on renal replacement therapy : an epidemiologic study .", "label": "", "metadata": {}, "score": "74.71939"}
{"text": "Joint aches .Nausea .Over the Counter Medications .Sodium Bicarbonate .Typically taken orally , sodium bicarbonate may be ordered if you develop a condition called metabolic acidosis .", "label": "", "metadata": {}, "score": "74.78065"}
{"text": "PubMed View Article .Foley RN , Li S , Liu J , Gilbertson DT , Chen SC , Collins AJ : The fall and rise of parathyroidectomy in U.S. hemodialysis patients , 1992 to 2002 .", "label": "", "metadata": {}, "score": "74.871574"}
{"text": "Relapses of secondary hyperparathyroidism ( SHPTH ) after parathyroidectomy ( PTx ) in haemodialysis patients are relatively frequent .Calcimimetics ( cinacalcet HCl ) offer a new therapeutic opportunity for their treatment .", "label": "", "metadata": {}, "score": "74.89722"}
{"text": "References .G. M. London , A. P. Guerin , S. J. Marchais et al . , \" Cardiac and arterial interactions in end - stage renal disease , \" Kidney International , vol .", "label": "", "metadata": {}, "score": "75.05444"}
{"text": "No significant difference was noted in levels of alkaline phosphatase , hemoglobin , and albumin between the two groups .Goal Attainment of K / DOQI and KDIGO .", "label": "", "metadata": {}, "score": "75.08202"}
{"text": "Participants were recruited from dialysis clinics and hospitals between August 2006 to Jan 2008 from 22 countries .Pre - Assignment Details .Significant events and approaches for the overall study following participant enrollment , but prior to group assignment .", "label": "", "metadata": {}, "score": "75.21751"}
{"text": "o how to take pantoprazole sodium delayed - release tablets .What are the possible side effects of pantoprazole sodium delayed - release tablets ?Pantoprazole sodium delayed - release tablets can cause serious side effects including .", "label": "", "metadata": {}, "score": "75.22081"}
{"text": "This new class of agents augments the sensitivity of CaSR of parathyroid glands to extra- cellular calcium ( Ca ) concentrations , by that way causing both the suppression of parathyroid hormone ( PTH ) secretion [ 5 ] and of cellular proliferation [ 6].", "label": "", "metadata": {}, "score": "75.277306"}
{"text": "J Am Soc Nephrol 2001 ; 12 : 1242 - 1248 4 .Tominaga Y , Uchida K , Haba T et al .More than 1,000 cases of total parathyroidectomy with forearm autograft for renal hyperparathyroidism .", "label": "", "metadata": {}, "score": "75.27783"}
{"text": "People who are taking multiple daily doses of proton pump inhibitor medicines for a long period of time may have an increased risk of fractures of the hip , wrist or spine .", "label": "", "metadata": {}, "score": "75.28993"}
{"text": "People who are taking multiple daily doses of proton pump inhibitor medicines for a long period of time may have an increased risk of fractures of the hip , wrist or spine .", "label": "", "metadata": {}, "score": "75.28993"}
{"text": "Kidney Int 2005 ; 67 : 467 - 476 23 .Kawata T , Imanishi Y , Kobayashi K et al .Direct in vitro evidence of the suppressive effect of cinacalcet HCl on para- thyroid hormone secretion in human parathyroid cells with pathologically reduced calcium - sensing receptor levels .", "label": "", "metadata": {}, "score": "75.29105"}
{"text": "The latter is particularly important in patients undergoing peritoneal dialysis who are exposed at length to transfers of mass and therefore a long - lasting , harmful positive calcium balance .", "label": "", "metadata": {}, "score": "75.29335"}
{"text": "Stomach lining weakening with long - term use .Vitamin B-12 deficiency .Your doctor may stop Pantoprazole if these symptoms happen .Low magnesium levels in your body .", "label": "", "metadata": {}, "score": "75.298584"}
{"text": "[5 ] study did not make a significant difference in the time period of the current study .Some PTX procedures may have been missed if they were not coded .", "label": "", "metadata": {}, "score": "75.42929"}
{"text": "Because it produced the most efficient number of points for this analysis , bimonthly PTX incidence rates were calculated throughout the study duration .The adequate candidate model was chosen according to published guidelines ( parameters significance , graphical evaluation of residuals , and Akaike Information Criterion ) [ 13 , 14 ] .", "label": "", "metadata": {}, "score": "75.51294"}
{"text": "Patients at risk for osteoporosis - related fractures should be managed according to established treatment guidelines [ see Dosage and Administration ( 2 ) and Adverse Reactions ( 6.2 ) ] .", "label": "", "metadata": {}, "score": "75.57333"}
{"text": "Rates of PTX varied considerably between 1992 and 2007 [ 5 - 8 ] .These fluctuations were attributed to availability of new therapeutic options ( vitamin D analogs and non - calcium - containing phosphate binders ) and publication of practice guidelines [ 5 ] .", "label": "", "metadata": {}, "score": "75.57435"}
{"text": "Allocation : Non - Randomized Endpoint Classification : Safety / Efficacy Study Intervention Model : Single Group Assignment Masking : Open Label Primary Purpose : Treatment .", "label": "", "metadata": {}, "score": "75.63622"}
{"text": "PROTONIX I.V. for Injection should be reconstituted with 10 mL of 0.9 % Sodium Chloride Injection , USP , to a final concentration of approximately 4 mg / mL. The reconstituted solution may be stored for up to 24 hours at room temperature prior to intravenous infusion and does not need to be protected from light .", "label": "", "metadata": {}, "score": "75.66392"}
{"text": "Conclusions .A decreased annual rate of PTX was found after January 2006 , corresponding to cinacalcet availability .However , decreased rates may be due to other factors occurring simultaneously with cinacalcet introduction and further studies are needed to confirm these findings .", "label": "", "metadata": {}, "score": "75.67536"}
{"text": "Nephrol Dial Transplant 2006 ; 21 : 968 - 974 15 .Schantz A , Castleman B. Parathyroid carcinoma : A study of 70 cases .", "label": "", "metadata": {}, "score": "75.68442"}
{"text": "There are no medications to cure or reverse kidney failure .Over - the - Counter Medications .Prescription Medications .Cinacalcet HCL .In chronic renal disease , a disturbance in calcium , phosphate , and vitamin D metabolism leads to a condition called secondary hyperparathyroidism .", "label": "", "metadata": {}, "score": "75.75916"}
{"text": "55.4SD months ( range 64 - 240 ) .These patients had mean serum iPTH levels of 996.2 ?53.8pg / ml ( range 370.4 - 1800.2 ) .", "label": "", "metadata": {}, "score": "76.0289"}
{"text": "Phosphate and Actions Produced on Vascular Calcifications .The recently published KDIGO guidelines , as well as the previous KDOQI version , underline the importance of maintaining phosphate levels within the normal range from the earliest stages of CKD .", "label": "", "metadata": {}, "score": "76.03558"}
{"text": "Patients should be instructed to inform their healthcare provider of any other medications they are currently taking , including over - the - counter medications , as well as allergies to any medications .", "label": "", "metadata": {}, "score": "76.06609"}
{"text": "\" [ Show abstract ] [ Hide abstract ] ABSTRACT : We evaluated the efficacy of percutaneous ethanol injection therapy ( PEIT ) as a therapeutic option for recurrence of secondary hyperparathyroidism after subtotal parathyroidectomy in ESRD patients .", "label": "", "metadata": {}, "score": "76.12248"}
{"text": "PTX was the primary outcome and was identified through hospital discharge summary procedure codes ( CCP : 19.71 , 19.72 ; CCI : 1FV83 , 1FV87 , 1FV89 ) and RAMQ physician claim code ( 6186 , 6185 , 6181 ) .", "label": "", "metadata": {}, "score": "76.45802"}
{"text": "Advise patients to immediately report and seek care for any cardiovascular or neurological symptoms including palpitation , dizziness , seizures , and tetany as these may be signs of hypomagnesemia .", "label": "", "metadata": {}, "score": "76.62513"}
{"text": "Advise patients to immediately report and seek care for any cardiovascular or neurological symptoms including palpitation , dizziness , seizures , and tetany as these may be signs of hypomagnesemia .", "label": "", "metadata": {}, "score": "76.62513"}
{"text": "570 - 574 , 1998 .View at Google Scholar \u00b7 View at Scopus .J. Blacher , A. P. Guerin , B. Pannier , S. J. Marchais , M. E. Safar , and G. M. London , \" Impact of aortic stiffness on survival in end - stage renal disease , \" Circulation , vol .", "label": "", "metadata": {}, "score": "76.66219"}
{"text": "All statistical inferences were performed using the SPSS software package , version 10 ( SPSS Inc. , Chicago , IL , USA ) .Results The clinical and demographic characteristics of the two groups are shown in Table 1 .", "label": "", "metadata": {}, "score": "76.681885"}
{"text": "The apparent volume of distribution of pantoprazole is approximately 11.0 - 23.6 L , distributing mainly in extracellular fluid .The serum protein binding of pantoprazole is about 98 % , primarily to albumin .", "label": "", "metadata": {}, "score": "76.68656"}
{"text": "The apparent volume of distribution of pantoprazole is approximately 11.0 - 23.6 L , distributing mainly in extracellular fluid .The serum protein binding of pantoprazole is about 98 % , primarily to albumin .", "label": "", "metadata": {}, "score": "76.68656"}
{"text": "Table 2 : A study analyzing the effect of non - calcium - based phosphate binders .Discussion .In spite of the lack of evidence from randomized controlled trials ( RCTs ) to demonstrate that a lowering of phosphorus levels impacts clinical outcomes , it may be reasonable to lower phosphorus in CKD patients with hyperphosphatemia using phosphate binders .", "label": "", "metadata": {}, "score": "76.7611"}
{"text": "Non - calcium phosphate binders available currently are aluminium hydroxide , ferric citrate , magnesium carbonate , sevelamer HCl and sevelamer carbonate , and lanthanum carbonate .", "label": "", "metadata": {}, "score": "76.826004"}
{"text": "Because these reactions are reported voluntarily from a population of uncertain size , it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure .", "label": "", "metadata": {}, "score": "76.91747"}
{"text": "600 - 608 , 1996 .View at Google Scholar \u00b7 View at Scopus .J. Blacher , B. Pannier , A. P. Guerin , S. J. Marchais , M. E. Safar , and G. M. London , \" Carotid arterial stiffness as a predictor of cardiovascular and all- cause mortality in end - stage renal disease , \" Hypertension , vol .", "label": "", "metadata": {}, "score": "76.94547"}
{"text": "PROTONIX I.V. 40 mg once daily does not raise gastric pH to levels sufficient to contribute to the treatment of such life - threatening conditions .", "label": "", "metadata": {}, "score": "77.046005"}
{"text": "Abbreviations : PTX , parathyroidectomy ; py , person - year .Trends in medication use are given in Figure 4 and average daily doses are shown in Table 2 .", "label": "", "metadata": {}, "score": "77.05769"}
{"text": "Another explanation would be a change of indication or physician attitude toward PTX .For example , physicians may now tolerate higher PTH level thresholds before considering a PTX .", "label": "", "metadata": {}, "score": "77.07629"}
{"text": "These 12 haemodialysis patients ( all of them more than 18 years old and clinically stable ) were enrolled into the present study after written informed consent .", "label": "", "metadata": {}, "score": "77.22182"}
{"text": "CYP2C19 displays a known genetic polymorphism due to its deficiency in some subpopulations ( e.g. , approximately 3 % of Caucasians and African - Americans and 17 % to 23 % of Asians are poor metabolizers ) .", "label": "", "metadata": {}, "score": "77.27571"}
{"text": "For early - stage UHPT , it has been recognized that conventional management with dietary phosphorus restriction , phosphate binder and active vitamin D has distinct efficacy on renal osteodystrophy and additional important health benefits [ 10 , 20 ] .", "label": "", "metadata": {}, "score": "77.46904"}
{"text": "Vitamin B-12 deficiency .Your doctor may stop pantoprazole sodium delayed - release tablets if these symptoms happen .Low magnesium levels in your body .", "label": "", "metadata": {}, "score": "77.52796"}
{"text": "Pantoprazole is not for children under 5 years old .Who should not take Pantoprazole ?Do not take Pantoprazole if you are : . allergic to any of the ingredients in Pantoprazole .", "label": "", "metadata": {}, "score": "77.58055"}
{"text": "In this large population - based study , a significant drop in PTX rates among patients receiving dialysis after January 1 , 2006 is shown .", "label": "", "metadata": {}, "score": "77.65467"}
{"text": "Calcimimetics have also shown good therapeutic efficacy in counteracting hypercalcaemia in persistent SHPTH after successful kidney transplan- tation , with a reported variable outcome of renal function [ 18 - 20].", "label": "", "metadata": {}, "score": "77.96175"}
{"text": "EBSCO DynaMed website .Updated April 22 , 2013 .Accessed July 2 , 2013 .Coladonato JA .Control of hyperphosphatemia among patients with ESRD .", "label": "", "metadata": {}, "score": "78.23346"}
{"text": "Li S , Chen YW , Peng Y , Foley RN , St Peter WL : Trends in parathyroidectomy rates in US hemodialysis patients from 1992 to 2007 .", "label": "", "metadata": {}, "score": "78.35556"}
{"text": "Effects of thecalcimimetic cardiovascular disease , fracture , and health - related quality of life in secondary hyperparathyroidism .Kidney Int 2005 ; 68 : 1793 - 1800 18 .", "label": "", "metadata": {}, "score": "78.45612"}
{"text": "However , to date , no published reports or trials have been made available that demonstrate activity of this phosphate binder on vascular calcifications .Sevelamer from CKD Stage 5D : Effects and Comparison with Calcium - Based Phosphate Binders .", "label": "", "metadata": {}, "score": "78.4789"}
{"text": "Novel insights into the pathophysiology of calcium and phosphate handling , especially the discovery of the phosphatonin FGF23 , suggest that a more complex assessment of phosphate balance is warranted .", "label": "", "metadata": {}, "score": "78.49742"}
{"text": "The structural formula is : .Pantoprazole sodium is a white to off - white crystalline powder and is racemic .Pantoprazole has weakly basic and acidic properties .", "label": "", "metadata": {}, "score": "78.515015"}
{"text": "Increases in INR and prothrombin time may lead to abnormal bleeding and even death .Patients treated with proton pump inhibitors and warfarin concomitantly should be monitored for increases in INR and prothrombin time .", "label": "", "metadata": {}, "score": "78.588264"}
{"text": "The structural formula is : .Pantoprazole sodium sesquihydrate is a white to off - white crystalline powder and is racemic .Pantoprazole has weakly basic and acidic properties .", "label": "", "metadata": {}, "score": "78.62092"}
{"text": "Calcium supplements are given to bind phosphate to maintain phosphate levels within a range that will not increase bone loss .These drugs are taken orally .", "label": "", "metadata": {}, "score": "78.794876"}
{"text": "The incidence rates of adverse reactions and laboratory abnormalities in patients aged 65 years and older were similar to those associated with patients younger than 65 years of age .", "label": "", "metadata": {}, "score": "78.80708"}
{"text": "The incidence rates of adverse reactions and laboratory abnormalities in patients aged 65 years and older were similar to those associated with patients younger than 65 years of age .", "label": "", "metadata": {}, "score": "78.80708"}
{"text": "The distribution of UHPT severity did not differ between the two groups .There were no significant differences in their baseline levels of iPTH , calcium , phosphorous , calcium phosphate product ( Ca \u00d7 P ) , alkaline phosphatase and hemoglobin .", "label": "", "metadata": {}, "score": "78.878235"}
{"text": "461.7 to 573.7 ? 128.7pg / ml , P\u00bc0.01 , parathyroid cells notoriously , arenot 4 of 7C. Page 5 .Table 3 .Rx 2 .", "label": "", "metadata": {}, "score": "78.90793"}
{"text": "Laboratory - based experimental data suggest that hyperphosphatemia may directly cause or exacerbate other aspects of CKD - MBD , specifically arterial calcification .Beta - glycerophosphate , a phosphate donor , and uremic sera induce calcification and osteopontin expression in bovine vascular smooth muscle ( BVSM ) cells [ 16 ] .", "label": "", "metadata": {}, "score": "79.04612"}
{"text": "Ethical considerations .This study was approved by the Government of Qu\u00e9bec ethics committee ( Commission d'acc\u00e8s \u00e0 l'information ) and Maisonneuve - Rosemont Hospital ethics committee , and informed consent was waived .", "label": "", "metadata": {}, "score": "79.164085"}
{"text": "The major factors responsible for stimulating parathyroid gland function in renal failure involve hyperphosphatemia , hypocalcemia , decreased production of 1,25-dihydroxyvitamin D and peripheral resistance to parathyroid hormone ( PTH ) [ 1 , 2 ] .", "label": "", "metadata": {}, "score": "79.29108"}
{"text": "General Disorders and Administration Conditions : asthenia , fatigue , malaise .Immune System Disorders : anaphylaxis ( including anaphylactic shock ) .Investigations : weight changes .", "label": "", "metadata": {}, "score": "79.42769"}
{"text": "In all cases , parathyroid carcinoma was diagnosed after PTx on the basis of local invasion ( No\u00bc5 ) , tumour pathology ( No\u00bc4 ) or distant metas- tases ( No\u00bc2 ) .", "label": "", "metadata": {}, "score": "79.476105"}
{"text": "The structural formula is : .Pantoprazole sodium sesquihydrate is a white to cream color powder and is racemic .Pantoprazole has weakly basic and acidic properties .", "label": "", "metadata": {}, "score": "79.481735"}
{"text": "Distribution .The apparent volume of distribution of pantoprazole is approximately 11 to 23.6 L , distributing mainly in extracellular fluid .The serum protein binding of pantoprazole is about 98 % , primarily to albumin .", "label": "", "metadata": {}, "score": "79.59952"}
{"text": "Metabolism and Nutritional Disorders : hyponatremia , hypomagnesemia .Musculoskeletal Disorders : rhabdomyolysis , bone fracture .Psychiatric Disorders : hallucination , confusion , insomnia , somnolence .", "label": "", "metadata": {}, "score": "79.681076"}
{"text": "Metabolism and Nutritional Disorders : hyponatremia , hypomagnesemia .Musculoskeletal Disorders : rhabdomyolysis , bone fracture .Psychiatric Disorders : hallucination , confusion , insomnia , somnolence .", "label": "", "metadata": {}, "score": "79.681076"}
{"text": "The present paper aims to analyze comparative and efficacy studies undertaken to assess particularly the impact on morbidity and mortality rates of non - calcium phosphate binders .", "label": "", "metadata": {}, "score": "79.7323"}
{"text": "The weakness of this study is constituted by the high presence of pre - existing calcifications in the patients investigated .Similar conclusions on CACS and mortality rates were reached by a recent meta - analysis of 2873 patients [ 33 ] .", "label": "", "metadata": {}, "score": "79.77457"}
{"text": "The incidence rates of adverse events and laboratory abnormalities in patients aged 65 years and older were similar to those associated with patients younger than 65 years of age .", "label": "", "metadata": {}, "score": "79.86249"}
{"text": "Clin J Am Soc Nephrol 2011 , 6 ( 4 ) : 913 - 921 .PubMed View Article .Goodman WG , Goldin J , Kuizon BD , Yoon C , Gales B , Sider D , Wang Y , Chung J , Emerick A , Greaser L , Elashoff RM , Salusky IB : Coronary - artery calcification in young adults with end - stage renal disease who are undergoing dialysis .", "label": "", "metadata": {}, "score": "80.21261"}
{"text": "A total of 12 795 chronic dialysis patients ( mean age 64 years , 39 % female , 82 % hemodialysis ) were followed for a mean follow - up of 3.3 years .", "label": "", "metadata": {}, "score": "80.43704"}
{"text": "Skin and Subcutaneous Tissue Disorders : severe dermatologic reactions ( some fatal ) , including erythema multiforme , Stevens - Johnson syndrome , and toxic epidermal necrolysis ( TEN , some fatal ) , and angioedema ( Quincke 's edema ) . 7 DRUG INTERACTIONS .", "label": "", "metadata": {}, "score": "80.55804"}
{"text": "Skin and Subcutaneous Tissue Disorders : severe dermatologic reactions ( some fatal ) , including erythema multiforme , Stevens - Johnson syndrome , and toxic epidermal necrolysis ( TEN , some fatal ) , and angioedema ( Quincke 's edema ) . 7 DRUG INTERACTIONS .", "label": "", "metadata": {}, "score": "80.55804"}
{"text": "Alfacalcidol and calcitriol are by far the two frequently used activated vitamin D products in Qu\u00e9bec .For all analyses , a p - value of less than 0.05 was considered statistically significant .", "label": "", "metadata": {}, "score": "80.70974"}
{"text": "[ Google Scholar ] [ CrossRef ] .Block , G.A. ; Martin , K.J. ; de Francisco , A.L. ; Turner , S.A. ; Avram , M.M. ; Suranyi , M.G. ; Hercz , G. ; Cunningham , J. ; Abu - Alfa , A.K. ; Messa , P. ; et al .", "label": "", "metadata": {}, "score": "80.725876"}
{"text": "Supplement , no . 111 , pp .S38 - 43 , 2008 .View at Google Scholar \u00b7 View at Scopus .G. A. Block , T. E. Hulbert - Shearon , N. W. Levin , and F. K. Port , \" Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients : a national study , \" American Journal of Kidney Diseases , vol .", "label": "", "metadata": {}, "score": "80.86153"}
{"text": "After 2006 , annual PTX rates remained between 3.0 and 4.6 /1000 py .While January 2006 was the only statistically significant cut - off point in our model , visually the change in rate appeared slightly before that and all cut - off dates between January 2005 and June 2006 showed a trend for a lower PTX rates .", "label": "", "metadata": {}, "score": "80.96495"}
{"text": "View at Publisher \u00b7 View at Google Scholar \u00b7 View at PubMed \u00b7 View at Scopus .S. A. Jamal , D. Fitchett , C. E. Lok , D. C. Mendelssohn , and R. T. Tsuyuki , \" The effects of calcium - based versus non - calcium - based phosphate binders on mortality among patients with chronic kidney disease : a meta - analysis , \" Nephrology Dialysis Transplantation , vol .", "label": "", "metadata": {}, "score": "81.07771"}
{"text": "18 , pp .2434 - 2439 , 1999 .View at Google Scholar \u00b7 View at Scopus . A. Y. M. Wang , M. Wang , J. Woo et al . , \" Cardiac valve calcification as an important predictor for all - cause mortality and cardiovascular mortality in long - term peritoneal dialysis patients : a prospective study , \" Journal of the American Society of Nephrology , vol .", "label": "", "metadata": {}, "score": "81.180275"}
{"text": "Soc .Nephrol .[ Google Scholar ] .Fukagawa , M. ; Yumita , S. ; Akizawa , T. ; Uchida , E. ; Tsukamoto , Y. ; Iwasaki , M. ; Koshikawa , S. ; KRN1493 study group .", "label": "", "metadata": {}, "score": "81.198006"}
{"text": "In recent years , a large number of therapeutic options have been successfully used in the treatment of secondary hyperparathyroidism ( SHPT ) , despite eliciting less marked effects on nonbone calcifications associated with CKD - MBD .", "label": "", "metadata": {}, "score": "81.283676"}
{"text": "Do not change the amount or the schedule .Do not stop taking them without talking to your doctor .Do not share them .Ask what the results and side effects may be .", "label": "", "metadata": {}, "score": "81.300186"}
{"text": "PubMed View Article .Jollis JG , Ancukiewicz M , DeLong ER , Pryor DB , Muhlbaier LH , Mark DB : Discordance of databases designed for claims payment versus clinical information systems .", "label": "", "metadata": {}, "score": "81.368835"}
{"text": "Do not split , chew , or crush Pantoprazole sodium delayed - release tablets .Distributed by Kremers Urban Pharmaceuticals Inc. Princeton , NJ 08540 , USA .", "label": "", "metadata": {}, "score": "81.41217"}
{"text": "Goodman WG .Recent developments in the management of secondary hyperparathyroidism .Kidney Int 2001 ; 59 : 1187 - 1201 6 .Silver J. Pathogenesis of parathyroid dysfunction in end - stage renal disease .", "label": "", "metadata": {}, "score": "81.472725"}
{"text": "Recently , Sage et al . showed that vascular calcifications produced as a result of uremic hyperphosphatemia are associated with vascular cell expression of osteogenic genes , including bone morphogenetic protein-", "label": "", "metadata": {}, "score": "81.72821"}
{"text": "Includes whether analysis was per protocol , intention to treat , or another method .Also provides relevant details such as imputation technique , as appropriate .", "label": "", "metadata": {}, "score": "81.77255"}
{"text": "Using a provincial administrative database , we included all adult patients receiving chronic dialysis treatments between 2001 and 2010 ( incident and prevalent ) in a time series analysis .", "label": "", "metadata": {}, "score": "81.96213"}
{"text": "4 , pp .607 - 617 , 1998 .View at Google Scholar \u00b7 View at Scopus .J. H. Ix , I. H. De Boer , C. A. Peralta et al . , \" Serum phosphorus concentrations and arterial stiffness among individuals with normal kidney function to moderate kidney disease in MESA , \" Clinical Journal of the American Society of Nephrology , vol .", "label": "", "metadata": {}, "score": "82.25963"}
{"text": "Time to Primary Composite Endpoint ( All - cause Mortality , Myocardial Infarction , Hospitalization for Unstable Angina , Heart Failure or Peripheral Vascular Event )", "label": "", "metadata": {}, "score": "82.46693"}
{"text": "The stability of the compound in aqueous solution is pH - dependent .The rate of degradation increases with decreasing pH. The reconstituted solution of PROTONIX I.V. for Injection is in the pH range 9.0 to 10.5 .", "label": "", "metadata": {}, "score": "82.48682"}
{"text": "Full to partial recovery of these effects were noted in animals of both age groups following a recovery period .14 CLINICAL STUDIES .14.1 Gastroesophageal Reflux Disease ( GERD ) Associated with a History of Erosive Esophagitis .", "label": "", "metadata": {}, "score": "82.65353"}
{"text": "Measured serum Ca levels were adjusted by albumin levels as follows , when they were less than 4.0g / dl : Calcium\u00bcmeasured levels ) ? 0.8 ] mg / dl [ 16].", "label": "", "metadata": {}, "score": "82.81419"}
{"text": "The stability of the compound in aqueous solution is pH - dependent .The rate of degradation increases with decreasing pH. At ambient temperature , the degradation half - life is approximately 2.8 hours at pH 5 and approximately 220 hours at pH 7.8 .", "label": "", "metadata": {}, "score": "82.84975"}
{"text": "The stability of the compound in aqueous solution is pH - dependent .The rate of degradation increases with decreasing pH. At ambient temperature , the degradation half - life is approximately 2.8 hours at pH 5 and approximately 220 hours at pH 7.8 .", "label": "", "metadata": {}, "score": "82.84975"}
{"text": "General Disorders and Administration Conditions : asthenia , fatigue , malaise .Hepatobiliary Disorders : hepatocellular damage leading to jaundice and hepatic failure .Immune System Disorders : anaphylaxis ( including anaphylactic shock ) .", "label": "", "metadata": {}, "score": "82.87195"}
{"text": "General Disorders and Administration Conditions : asthenia , fatigue , malaise .Hepatobiliary Disorders : hepatocellular damage leading to jaundice and hepatic failure .Immune System Disorders : anaphylaxis ( including anaphylactic shock ) .", "label": "", "metadata": {}, "score": "82.87195"}
{"text": "In addition , information on drugs dispensed to all individuals age 65 years and older , individuals on welfare and workers insured by the provincial drug plan is captured within the database .", "label": "", "metadata": {}, "score": "82.872894"}
{"text": "Parathyroidectomy rates by age categories .Age is calculated at cohort entry .Panel B .Parathyroidectomy rates by sex .Panel C .Parathyroidectomy rates for incident and prevalent patients .", "label": "", "metadata": {}, "score": "83.01718"}
{"text": "609 - 615 , 2009 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at PubMed \u00b7 View at Scopus . A. P. Sage , J. Lu , Y. Tintut , and L. L. Demer , \" Hyperphosphatemia - induced nanocrystals upregulate the expression of bone morphogenetic protein-2 and osteopontin genes in mouse smooth muscle cells in vitro , \" Kidney International , vol . 79 , no .", "label": "", "metadata": {}, "score": "83.19125"}
{"text": "Procrit .This drug is injected and used to treat anemia associated with renal failure .It stimulates the production of red blood cells .Possible side effects include : . Headache .", "label": "", "metadata": {}, "score": "83.34288"}
{"text": "Many people with low blood phosphorus take high doses of phosphorus and calcium medications .However , one side effect of these drugs is increased blood levels of parathyroid hormone ( PTH ) .", "label": "", "metadata": {}, "score": "83.38123"}
{"text": "Renal and Urinary Disorders : interstitial nephritis .Hepatobiliary Disorders : hepatocellular damage leading to jaundice and hepatic failure .Psychiatric Disorder : hallucinations , confusion , insomnia , somnolence .", "label": "", "metadata": {}, "score": "83.497055"}
{"text": "CYP2C19 displays a known genetic polymorphism due to its deficiency in some sub - populations ( e.g. , 3 % of Caucasians and African - Americans and 17 - 23 % of Asians ) .", "label": "", "metadata": {}, "score": "83.52397"}
{"text": "Mouth dryness .Weakness .Frequent urination .Sevelamer .Common name : Renagel .This agent , which is taken by mouth , binds phosphate to prevent increased blood phosphate levels that can lead to weakening of bones .", "label": "", "metadata": {}, "score": "83.69649"}
{"text": "Miki H , Sumitomo M , Inoue H , Kita S , Monden Y. Parathyroid carcinoma in patients with chronic renal failure on maintenance hemodialysis .", "label": "", "metadata": {}, "score": "83.78198"}
{"text": "[5 ] described PTX rates in the US from 1992 to 2007 .A PTX peak rate was found in 2002 ( 12.8 /1000 py ) followed by a decreasing rate until 2005 ( 5.4 /1000 py ) and then an increase again in 2006 - 2007 ( 8.6 /1000 py ) [ 5 ] .", "label": "", "metadata": {}, "score": "83.93016"}
{"text": "The longitudinal changes of parameters of CKD - mineral bone disease at baseline , 3 months , and 6 months after initiating treatment of moderate to severe UHPT is displayed in Table 2 .", "label": "", "metadata": {}, "score": "84.153885"}
{"text": "In the present paper we will focus mainly on vascular calcifications and how to personalize treatment with phosphate binders in an attempt to reduce the presence of calcifications on blood vessel walls .", "label": "", "metadata": {}, "score": "84.4008"}
{"text": "Patients were censored at PTX , death , kidney transplantation , emigration out of the province , or end of the study ( December 31 , 2010 ) .", "label": "", "metadata": {}, "score": "84.505135"}
{"text": "Table 7 : Long - Term Maintenance of Healing of Erosive Gastroesophageal Reflux Disease ( GERD Maintenance ) : Percentage of Patients Who Remained Healed .", "label": "", "metadata": {}, "score": "84.5892"}
{"text": "The most frequently occurring adverse reactions are listed in Table 3 .Body as a Whole : allergic reaction , pyrexia , photosensitivity reaction , facial edema .", "label": "", "metadata": {}, "score": "84.75057"}
{"text": "The most frequently occurring adverse reactions are listed in Table 3 .Body as a Whole : allergic reaction , pyrexia , photosensitivity reaction , facial edema .", "label": "", "metadata": {}, "score": "84.75057"}
{"text": "[ Google Scholar ] [ CrossRef ] .Clin .Am .Soc .Nephrol .[ Google Scholar ] [ CrossRef ] .Block , G.A. ; Zeig , S. ; Sugihara , J. ; Chertow , G.M. ; Chi , E.M. ; Turner , S.A. ; Bushinsky , D.A ; TARGET Investigators .", "label": "", "metadata": {}, "score": "84.89522"}
{"text": "Chem .[ Google Scholar ] .Krajisnik , T. ; Bj\u00f6rklund , P. ; Marsell , R. ; Ljunggren , O. ; Akerstr\u00f6m , G. ; Jonsson , K.B. ; Westin , G. ; Larsson , T.E. Fibroblast growth factor-23 regulates parathyroid hormone and 1alpha - hydroxylase expression in cultured bovine parathyroid cells .", "label": "", "metadata": {}, "score": "84.91475"}
{"text": "2005;16:S107 - 114 .Malluche HH , Mawad H , et al .The importance of bone health in end - stage renal disease : out of the frying pan , into the fire ?", "label": "", "metadata": {}, "score": "85.00983"}
{"text": "[ Google Scholar ] [ CrossRef ] .J. Ren .Nutr .[ Google Scholar ] [ CrossRef ] .Block , G.A. ; Klassen , P.S. ; Lazarus , J.M. ; Ofsthun , N. ; Lowrie , E.G. ; Chertow , G.M. Mineral metabolism , mortality , and morbidity in maintenance hemodialysis .", "label": "", "metadata": {}, "score": "85.0753"}
{"text": "In the thyroid gland , treatment at 200 mg / kg / day produced increased incidences of follicular cell adenomas and carcinomas for both male and female rats .", "label": "", "metadata": {}, "score": "85.09184"}
{"text": "In the gastric fundus , treatment at 5 to 50 mg / kg / day produced enterochromaffin - like ( ECL ) cell hyperplasia and benign and malignant neuroendocrine cell tumors .", "label": "", "metadata": {}, "score": "85.238235"}
{"text": "Calcium phosphate binders such as calcium carbonate or acetate are still widely used today .Evidence of an increased risk of onset and progression of nonbone , particularly vascular , calcifications has led to the use of caution by nephrologists , in spite of the markedly lower costs compared to the price of the new non - calcium .", "label": "", "metadata": {}, "score": "85.252014"}
{"text": "Call your healthcare provider if you develop side effects from the medications or you have : .Revision Information .This content is reviewed regularly and is updated when new and relevant evidence is made available .", "label": "", "metadata": {}, "score": "85.38568"}
{"text": "Low magnesium can happen in some people who take a proton pump inhibitor medicine for at least 3 months .If low magnesium levels happen , it is usually after a year of treatment .", "label": "", "metadata": {}, "score": "85.68461"}
{"text": "Low magnesium can happen in some people who take a proton pump inhibitor medicine for at least 3 months .If low magnesium levels happen , it is usually after a year of treatment .", "label": "", "metadata": {}, "score": "85.68461"}
{"text": "In opposition to ARIMA models , Poisson regression does not account for the dependence between measures seen in our situation ( a patient may be present in different intervals ) , but its results are more intuitive and may help validate results from ARIMA .", "label": "", "metadata": {}, "score": "85.8253"}
{"text": "5.3 Injection Site Reactions .5.4 Potential for Exacerbation of Zinc Deficiency .PROTONIX contains edetate disodium ( the salt form of EDTA ) , a chelator of metal ions including zinc .", "label": "", "metadata": {}, "score": "85.85123"}
{"text": "On the other hand , frequent use of aluminum hydroxide is noted in our study , which is because of the severity of UHPT in our subjects and they were prone to suffer hypercalcemia under administration of calcium - based phosphate binders .", "label": "", "metadata": {}, "score": "86.25838"}
{"text": "An excess of phosphorus represents an independent risk factor for cardiovascular morbidity and mortality in patients with advanced CKD .Options available for use in the treatment of hyperphosphatemia are severe control of dietary phosphorus intake [ 6 ] , use of phosphate binders [ 7 ] , and optimized phosphorus output choosing high - efficiency dialysis as high flux - methodology [ 8 - 10 ] .", "label": "", "metadata": {}, "score": "86.41299"}
{"text": "Bimonthly rates of PTX are given in Figure 2 .The average rate before cinacalcet approval was 11.4 /1000 py and was 3.6 /1000 py after cinacalcet reimbursement .", "label": "", "metadata": {}, "score": "86.47348"}
{"text": "Autoregressive integrated moving average ( ARIMA ) intervention models were used to analyze the effect of cinacalcet availability on PTX rates .The ARIMA intervention model is a specific time series model .", "label": "", "metadata": {}, "score": "86.52401"}
{"text": "Gastric alterations , including increased stomach weights , increased incidence of eosinophilic chief cells in adult and neonatal / juvenile rats , and atrophy of chief cells in adult rats and in neonatal / juvenile dogs , were observed in the fundic mucosa of stomachs in repeated - dose studies .", "label": "", "metadata": {}, "score": "86.57863"}
{"text": "Gastric alterations , including increased stomach weights , increased incidence of eosinophilic chief cells in adult and neonatal / juvenile rats , and atrophy of chief cells in adult rats and in neonatal / juvenile dogs , were observed in the fundic mucosa of stomachs in repeated - dose studies .", "label": "", "metadata": {}, "score": "86.57863"}
{"text": "Gastric alterations , including increased stomach weights , increased incidence of eosinophilic chief cells in adult and neonatal / juvenile rats , and atrophy of chief cells in adult rats and in neonatal / juvenile dogs , were observed in the fundic mucosa of stomachs in repeated - dose studies .", "label": "", "metadata": {}, "score": "86.57863"}
{"text": "Am J Kidney Dis 2003 ; 42 [ Suppl 3 ] : S1-S201 10 .Quarles LD , Sherrard DJ , Adler S et al .", "label": "", "metadata": {}, "score": "86.87077"}
{"text": "New markers , such as FGF-23 , have been identified as inducers of vascular calcification and cardiovascular disease in CKD .Therefore , the use of calcium - free phosphate binders may reduce the risk of cardiovascular disease by reducing both serum phosphate and FGF-23 levels [ 38 ] .", "label": "", "metadata": {}, "score": "87.01519"}
{"text": "Competing interests .This work was supported by an unrestricted grant from Amgen Canada .Dr. Lafrance is supported by a KRESCENT New Investigator Award ( public funding ) and has received advisory - board and lecture fees from Amgen Canada for unrelated work .", "label": "", "metadata": {}, "score": "87.069595"}
{"text": "PTX rates did not differ by gender .However , trends of PTX rates were similar across strata .Parathyroidectomy rates by age , sex , and incidence / prevalence .", "label": "", "metadata": {}, "score": "87.369255"}
{"text": "In the gastric fundus , treatment at 0.5 to 200 mg / kg / day produced enterochromaffin - like ( ECL ) cell hyperplasia and benign and malignant neuroendocrine cell tumors in a dose - related manner .", "label": "", "metadata": {}, "score": "87.66998"}
{"text": "These findings prompt further research into the potential of pyrophosphate as treatment for vascular calcification in chronic kidney disease patients [ 21 ] .Methods Applied in Literature Review .", "label": "", "metadata": {}, "score": "87.859055"}
{"text": "Eligibility : . -Individuals between 18 and 70 years of age who have different forms of hypophosphatemic rickets and tumor - induced hypophosphatemia .Participants will have up to 25 study visits over about 28 weeks .", "label": "", "metadata": {}, "score": "88.05626"}
{"text": "PubMed View Article .K / DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease Am J Kidney Dis 2003 , 42 ( 4 Suppl 3 ) : S1-S201 .", "label": "", "metadata": {}, "score": "88.36919"}
{"text": "The aim of this paper therefore is to evaluate which phosphate binders are characterised by the above action and the mechanisms through which these are manifested .", "label": "", "metadata": {}, "score": "88.36955"}
{"text": "High inorganic phosphate levels in vitro stimulate the osteogenic conversion of smooth muscle cells ; however , the mechanism governing this is not clear .We found that high - phosphate medium increased the expression of BMP-2 and OPN in mouse smooth muscle cells in culture .", "label": "", "metadata": {}, "score": "88.52742"}
{"text": "J. Med .[ Google Scholar ] [ CrossRef ] .Shoji , T. ; Shinohara , K. ; Kimoto , E. ; Emoto , M. ; Tahara , H. ; Koyama , H. ; Inaba , M. ; Fukumoto , S. ; Ishimura , E. ; Miki , T. ; et al .", "label": "", "metadata": {}, "score": "88.58788"}
{"text": "Meanwhile , as described in our previous study , the disturbance of bone mineral metabolism was associated with chronic inflammation in chronic dialysis patients [ 6 ] .", "label": "", "metadata": {}, "score": "88.8698"}
{"text": "This can involve induction of osteochondrogenic programs of gene expression in vascular smooth muscle cells ( VSMCs ) [ 19 ] .The uremic sera - induced osteopontin expression in BVSMC is partially mediated through alkaline phosphatase activity and an Na / Pi cotransporter - dependent mechanism .", "label": "", "metadata": {}, "score": "88.90219"}
{"text": "Mechanisms of Action .The mechanism through which non - calcium phosphate binders exert their action and slow down progression of vascular calcifications is still unclear and remains to be clarified .", "label": "", "metadata": {}, "score": "89.448425"}
{"text": "Large epidemiological studies have consistently shown the importance of hyperphosphatemia as a predictor of mortality in CKD stage 5 patients receiving dialysis .Experimental data suggest a direct causal relationship between phosphorus and several components of CKD - MBD , specifically SHTP bone abnormalities and calcitriol deficiency .", "label": "", "metadata": {}, "score": "89.64488"}
{"text": "Tell your doctor right away if you have any of these symptoms : . seizures . dizziness . abnormal or fast heartbeat . jitteriness .jerking movements or shaking ( tremors ) .", "label": "", "metadata": {}, "score": "90.24298"}
{"text": "cellulosic membrane with a surface area ranging from 1.5 to 2.0m2was utilized ; dialysate and blood flows were respec- tively 500 and 300ml / min .", "label": "", "metadata": {}, "score": "90.36983"}
{"text": "Statistical analysis was performed using SPSS version 17.0 ( SPSS Inc. , Chicago , IL ) .All categorical data were provided for absolute counts or percentages , whereas mean value \u00b1 standard deviation ( SD ) was presented as continuous data .", "label": "", "metadata": {}, "score": "90.66383"}
{"text": "The iPTH was determined using direct chemiluminescent immunoassay ( Intact PTH ; Siemens Healthcare Diagnostics , INC , Erlangen , Germany ) with a normal range of 12 - 72 pg / mL. Serum calcium and phosphorous levels were analyzed by an onsite laboratory using standard methods .", "label": "", "metadata": {}, "score": "90.76233"}
{"text": "A fundamental impetus in the study of compression exerted by calcium deposits in the vessels was provided by Raggi using highly advanced procedures such as electron - beam computed tomography ( EBCT ) , particularly to assess the involvement of coronary arteries [ 5 ] .", "label": "", "metadata": {}, "score": "90.93587"}
{"text": "7.3mg2/dl2 ; Table 1 .31.3 Controls 7 8 9 10 11 12 M F F M M M 24 64 51 47 48 45 48.2 ?", "label": "", "metadata": {}, "score": "91.157036"}
{"text": "Histological studies of the parathyroid glands with light microscopy were performed on seven serial sections of the glands .Diffuse hyperplasia was defined as increased numbers of parenchymal cells with normal lobular struc- tures , and nodular hyperplasia as at least one well circumscribed , encapsulated and virtually fat cell - free accu- mulation of parenchymal cells [ 14].", "label": "", "metadata": {}, "score": "91.2997"}
{"text": "Am .J. Kidney Dis .2003 , 42 , S1-S201 .Kidney Disease : Improving Global Outcomes ( KDIGO ) CKD - MBD Work Group .", "label": "", "metadata": {}, "score": "91.893486"}
{"text": "The high density of ECL cells in the rat stomach makes this species highly susceptible to the proliferative effects of elevated gastrin concentrations produced by proton pump inhibitors .", "label": "", "metadata": {}, "score": "91.96086"}
{"text": "The high density of ECL cells in the rat stomach makes this species highly susceptible to the proliferative effects of elevated gastrin concentrations produced by proton pump inhibitors .", "label": "", "metadata": {}, "score": "91.96086"}
{"text": "The high density of ECL cells in the rat stomach makes this species highly susceptible to the proliferative effects of elevated gastrin concentrations produced by proton pump inhibitors .", "label": "", "metadata": {}, "score": "91.96086"}
{"text": "Hyperphosphatemia has been associated with a poor outcome and mortality in CKD stage 5D and high normal serum phosphorus levels ; CKD patients have the same problem until stage 3 .", "label": "", "metadata": {}, "score": "92.08244"}
{"text": "In Canada , a new drug can not be marketed before being approved by Health Canada , which evaluates efficacy and safety of the drug .", "label": "", "metadata": {}, "score": "92.08801"}
{"text": "PEIT is an effective treatment to control recurrences of secondary hyperparathyroidism postsubtotal parathyroidectomy .[ Show abstract ] [ Hide abstract ] ABSTRACT : Secondary hyperparathyroidism ( high - turnover bone disease , or HTBD ) is manifested by elevated parathyroid hormone ( PTH ) levels .", "label": "", "metadata": {}, "score": "92.11761"}
{"text": "Abbreviations : Ca , calcium - containing phosphate binders ; Mg , magnesium - containing phosphate binders ; Al , aluminum - containing phosphate binders .", "label": "", "metadata": {}, "score": "92.37715"}
{"text": "366 - 373 , 2006 .View at Google Scholar \u00b7 View at Scopus Medications for End - stage Renal Disease ( ESRD ) .The information provided here is meant to give you a general idea about each of the medications listed below .", "label": "", "metadata": {}, "score": "92.46669"}
{"text": "An aging population may lead to lower PTX rates while an increasing proportion of prevalent patients may increase PTX rates .However , the population characteristics did not change much during the study years and the same PTX trend pattern was seen among subgroups ( Figure 3 ) .", "label": "", "metadata": {}, "score": "92.546326"}
{"text": "Policies for reimbursement of drugs vary by provinces .For the provincial drug plan in Qu\u00e9bec , decision to reimburse or not a drug is recommended by a provincial committee from the Institut national d'excellence en sant\u00e9 et en services sociaux ( INESSS ) , which evaluates its cost - effectiveness ratio and possible financial burden .", "label": "", "metadata": {}, "score": "92.604004"}
{"text": "P\u00bcnot significant .Table 2 . 6.9 NS 0.01 0.017 0.08 0.01 NS 0.021 0.01 0.032 47.7 ? 0.6 0.007 0.01 NS NS NS Both Wilcoxon test for paired data ( ?", "label": "", "metadata": {}, "score": "92.60771"}
{"text": "Ask your doctor if you need to take any special precautions .Use each of these medications only as recommended by your doctor , and according to the instructions provided .", "label": "", "metadata": {}, "score": "93.31979"}
{"text": "J Am Stat Assoc 1975 , 70 ( 349 ) : 70 - 79 .View Article .U.S. Renal Data System : USRDS 2011Annual Data Report : Atlas of Chronic Kidney Disease and End - Stage Renal Disease in the United States .", "label": "", "metadata": {}, "score": "93.39916"}
{"text": "The mean annual incidence of first PTx is about 30 per 1000 patient years in those dialysis patients treated for more than 10 years [ 3].", "label": "", "metadata": {}, "score": "93.45067"}
{"text": "Therefore , prevention and control of UHPT is crucial for dialysis patients as the excessive parathyroid hormone exerts systemic toxicity .During the past decades , treatment of UHPT has been more advanced and evolved based on new insights into its pathogenesis .", "label": "", "metadata": {}, "score": "93.768616"}
{"text": "Blood and urine samples will be collected .Up to three more lab visits for blood and urine tests will be required before treatment .Imaging studies of the bones , spine , and kidneys will be performed .", "label": "", "metadata": {}, "score": "93.97295"}
{"text": "Ann Intern Med 1993 , 119 ( 8) : 844 - 850 .PubMed View Article .Tamblyn R , Reid T , Mayo N , McLeod P , Churchill - Smith M : Using medical services claims to assess injuries in the elderly : sensitivity of diagnostic and procedure codes for injury ascertainment .", "label": "", "metadata": {}, "score": "94.09577"}
{"text": "PROTONIX I.V. for Injection may not be compatible with products containing zinc .When PROTONIX I.V. for Injection is administered through a Y - site , immediately stop use if precipitation or discoloration occurs .", "label": "", "metadata": {}, "score": "94.63109"}
{"text": "Choosing to participate in a study is an important personal decision .Talk with your doctor and family members or friends about deciding to join a study .", "label": "", "metadata": {}, "score": "94.83241"}
{"text": "Quick Links Connect With Us --Contact Us --Phone Directory --Request for Medical Records --Patient Portal --Classes and Events --Make An Appointment Quality & Privacy --Quality of Care --Patient Rights & Responsibilities --Privacy Policies --Patient Safety --Medication Safety HIGHLIGHTS OF PRESCRIBING INFORMATION .", "label": "", "metadata": {}, "score": "95.28032"}
{"text": "Magnesium Carbonate .For the sake of thoroughness , this paper on the action of non - calcium phosphate binders will conclude with a brief analysis of magnesium carbonate and another non - calcium binder was used only rarely .", "label": "", "metadata": {}, "score": "95.53848"}
{"text": "There were 12 795 patients on maintenance dialysis in Qu\u00e9bec between January 1 , 2001 and December 31 , 2010 .Derivation of the study cohort is detailed in Figure 1 .", "label": "", "metadata": {}, "score": "95.80001"}
{"text": "Methods .Study population and data sources .This study was conducted using the R\u00e9gie de l'assurance maladie du Qu\u00e9bec ( RAMQ ) database in the province of Qu\u00e9bec , Canada .", "label": "", "metadata": {}, "score": "98.14436"}
{"text": "Parathyroidectomy ( PTx ) is reserved for dialysis patients who have severe osteitis fibrosa , unresponsive to vitamin D therapy or in whom such a treatment is contraindicated .", "label": "", "metadata": {}, "score": "98.28355"}
{"text": "End - stage renal disease .National Institute of Diabetes & Digestive & Kidney Diseases website .Updated September 15 , 2010 .Accessed July 2 , 2013 .", "label": "", "metadata": {}, "score": "98.331696"}
{"text": "Authors ' contributions .All authors have approved the final version .Authors ' Affiliations .Centre de recherche H\u00f4pital Maisonneuve - Rosemont .D\u00e9partement de M\u00e9decine , Universit\u00e9 de Montr\u00e9al .", "label": "", "metadata": {}, "score": "98.57593"}
{"text": "Although carefully collected , accuracy can not be guaranteed .The impact factor represents a rough estimation of the journal 's impact factor and does not reflect the actual current impact factor .", "label": "", "metadata": {}, "score": "99.32186"}
{"text": "[ 1 ] .History of diabetes stratification factor from the interactive voice response system .[ 2 ] .Country stratification factor from the interactive voice response system .", "label": "", "metadata": {}, "score": "99.49718"}
{"text": "Full to partial recovery of these effects were noted in animals of both age groups following a recovery period .14 CLINICAL STUDIES .14.1 Erosive Esophagitis ( EE ) Associated with Gastroesophageal Reflux Disease ( GERD ) .", "label": "", "metadata": {}, "score": "99.54262"}
{"text": "PubMed View Article .Hipel KW , McLeod AI : Time Series Modelling of Water Resources and Environmental Systems .Amsterdam : Elsevier Scientific Publishing Company ; 1994 .", "label": "", "metadata": {}, "score": "99.626205"}
{"text": "Endocrinol .Metab .[ Google Scholar ] [ CrossRef ] .Endocrinology 1998 , 139 , 4391 - 4396 .[ Google Scholar ] [ CrossRef ] .", "label": "", "metadata": {}, "score": "100.119385"}
{"text": "Vascular calcifications produce a high impact on morbidity and mortality rates in patients affected by chronic kidney disease and mineral bone disorder ( CKD - MBD ) .", "label": "", "metadata": {}, "score": "100.308914"}
{"text": ": Aim : Uremic hyperparathyroidism ( UHPT ) has been shown to contribute to the development and progression of chronic kidney disease - mineral bone disorder .", "label": "", "metadata": {}, "score": "100.57535"}
{"text": "Lanthanum Carbonate .A positive action of lanthanum carbonate on vascular calcifications had already been hypothesized [ 52 ] ; although relatively few papers have been published to date to this regard , indications are provided of a positive effect of lanthanum carbonate on the progression of vascular calcifications .", "label": "", "metadata": {}, "score": "101.480515"}
{"text": "PubMed .Mayo NE , Goldberg MS , Levy AR , Danys I , Korner - Bitensky N : Changing rates of stroke in the province of Quebec , Canada : 1981 - 1988 .", "label": "", "metadata": {}, "score": "102.40451"}
{"text": "Email : basile.miulli@libero.it Nephrol Dial Transplant ( 2007 ) 1 of 7 doi:10.1093/ndt / gfm156 ?The Author [ 2007].Published by Oxford University Press on behalf of ERA - EDTA .", "label": "", "metadata": {}, "score": "103.67575"}
{"text": "PubMed .Levy AR , Mayo NE , Grimard G : Rates of transcervical and pertrochanteric hip fractures in the province of Quebec , Canada , 1981 - 1992 .", "label": "", "metadata": {}, "score": "103.68975"}
{"text": "Parathyroidectomy Hyperparathyroidism , Secondary Calcimimetic agents Renal dialysis Epidemiologic studies .Background .Secondary hyperparathyroidism is a common and serious disease that develops early in chronic kidney disease and continues to progress after subjects reach dialysis .", "label": "", "metadata": {}, "score": "103.970436"}
{"text": "8306 ) ; Fax : +886 - 7 - 732 - 2402 .Received : 16 February 2013 ; in revised form : 25 March 2013 / Accepted : 7 April 2013 / Published : 19 April 2013 .", "label": "", "metadata": {}, "score": "106.87166"}
{"text": "11 , pp .3215 - 3222 , 2006 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at PubMed \u00b7 View at Scopus .", "label": "", "metadata": {}, "score": "107.893456"}
{"text": "Rx 4 .Rx 5 .Rx 6 .\u00fe S 3.2\u00feCC 1 9.5 C 60\u00feS 2.4 4.2 4008.2 C 30\u00feCTR 0.25\u00feCC 1 7.7 C 30\u00feCTR 0.25\u00feCC 2 7.5 C 30\u00feCTR 0.25\u00feCC 2 8.3 C 30\u00feCTR 0.25\u00feCC 1 9.0 C 30 ?", "label": "", "metadata": {}, "score": "108.40715"}
{"text": "KDIGO clinical practice guideline for the diagnosis , evaluation , prevention , and treatment of Chronic Kidney Disease - Mineral and Bone Disorder ( CKD - MBD )", "label": "", "metadata": {}, "score": "108.48132"}
{"text": "159 - 168 , 2003 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . \"KDIGO Clinical Practice Guideline for the Diagnosis , Evaluation , Prevention , and Treatment of Chronic Kidney Disease - Mineral and Bone Disorder ( CKD - MBD ) .", "label": "", "metadata": {}, "score": "108.74083"}
{"text": "Over the last 10 years , it has become increasingly apparent that chronic kidney disease - mineral and bone disorder ( CKD - MBD ) is associated to extra - skeletal manifestations , particularly cardiovascular calcifications in patients at the more advanced stages of CKD .", "label": "", "metadata": {}, "score": "109.231766"}
{"text": "The disease is not confined to central blood vessels but also involves the iliac - femoral axis and all arteries in the limbs , thus producing a high impact on the quality of life , morbidity and mortality of these patients [ 1 - 3 ] .", "label": "", "metadata": {}, "score": "109.26167"}
{"text": "all Addendum Article Book Review Case Report Comment Commentary Communication Concept Paper Conference Report Correction Creative Data Descriptor Discussion Editorial Erratum Essay Interesting Images Letter New Book Received Obituary Opinion Project Report Reply Retraction Review Short Note Technical Note .", "label": "", "metadata": {}, "score": "110.29139"}
{"text": "445 - 454 , 2008 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at PubMed \u00b7 View at Scopus .51 , no .", "label": "", "metadata": {}, "score": "110.76552"}
{"text": "26 , no . 2 , pp .584 - 591 , 2011 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at PubMed .", "label": "", "metadata": {}, "score": "111.510216"}
{"text": "For general information , see Learn About Clinical Studies .Please refer to this study by its ClinicalTrials.gov identifier : NCT01748812 .Familial Hypophosphatemic Rickets Hypophosphatemia Osteomalacia Rickets , Hypophosphatemic Avitaminosis Bone Diseases Bone Diseases , Metabolic Calcium Metabolism Disorders Deficiency Diseases Genetic Diseases , Inborn Hypophosphatemia , Familial Kidney Diseases Malnutrition Metabolic Diseases .", "label": "", "metadata": {}, "score": "112.403854"}
{"text": "Canadian Institute for Health Information : Treatment of End - Stage Organ Failure in Canada , 2000 to 2009 ( 2011 Annual Report ) .Ottawa : CIHI ; 2011 .", "label": "", "metadata": {}, "score": "113.37833"}
{"text": "5 , pp .307 - 314 , 2003 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at PubMed \u00b7 View at Scopus .", "label": "", "metadata": {}, "score": "113.42645"}
{"text": "117 , no . 2 , pp .c83-c88 , 2011 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at PubMed .", "label": "", "metadata": {}, "score": "113.87505"}
{"text": "[ Google Scholar ] [ CrossRef ] .\u00a9 2013 by the authors ; licensee MDPI , Basel , Switzerland .Hypophosphatemia is a condition where a person has low levels of phosphorus in the blood .", "label": "", "metadata": {}, "score": "114.03639"}
{"text": "Territorial Department of Nephrology and Dialysis , ASL , Cagliari , Via Turati 4/C1 , 09045 Quartu Sant'Elena , Italy .Received 12 April 2011 ; Accepted 13 April 2011 .", "label": "", "metadata": {}, "score": "115.84717"}
{"text": "Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with questions regarding a medical condition .", "label": "", "metadata": {}, "score": "116.455185"}
{"text": "PubMed View Article .Pre - publication history .Copyright .\u00a9 Lafrance et al . ; licensee BioMed Central Ltd. 2013 .This article is published under license to BioMed Central Ltd.", "label": "", "metadata": {}, "score": "116.71405"}
{"text": "In press .29 , no . 2 , pp .163 - 176 , 2010 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at PubMed \u00b7 View at Scopus .", "label": "", "metadata": {}, "score": "116.98228"}
{"text": "Soc .Nephrol .[ Google Scholar ] [ CrossRef ] .JAMA 2011 , 305 , 1119 - 1127 .[ Google Scholar ] .", "label": "", "metadata": {}, "score": "117.97254"}
{"text": "This is an open access article distributed under the Creative Commons Attribution License , which permits unrestricted use , distribution , and reproduction in any medium , provided the original work is properly cited .", "label": "", "metadata": {}, "score": "119.389786"}
{"text": "10 , pp .3168 - 3174 , 2009 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at PubMed \u00b7 View at Scopus .", "label": "", "metadata": {}, "score": "119.40812"}
{"text": "Uremic hyperparathyroidism ( UHPT ) is one of the complications of chronic kidney disease ( CKD ) and is more commonly observed in patients undergoing dialysis .", "label": "", "metadata": {}, "score": "120.975494"}
{"text": "One cause of the condition is having too much fibroblast growth factor 23 ( FGF23 ) .FGF23 is a hormone that causes the kidney to get rid of phosphorus in the urine .", "label": "", "metadata": {}, "score": "121.63223"}
{"text": "For Permissions , please email : journals.permissions@oxfordjournals.org .Page 2 . frequent ranging from 10 % after 3 years to 30 % after 7 years [ 4].", "label": "", "metadata": {}, "score": "122.16857"}
{"text": "Division of Nephrology , Department of Internal Medicine , Kaohsiung Chang Gung Memorial Hospital , Chang Gung University College of Medicine , Kaohsiung , 833 , Taiwan .", "label": "", "metadata": {}, "score": "122.2646"}
{"text": "Service de n\u00e9phrologie , Centre hospitalier de l'Universit\u00e9 de Montr\u00e9al .Service de n\u00e9phrologie , H\u00f4pital du Sacr\u00e9 - C\u0153ur de Montr\u00e9al .Centre de recherche Centre hospitalier de l'Universit\u00e9 de Montr\u00e9al .", "label": "", "metadata": {}, "score": "123.272995"}
{"text": "Nephrol .Dial .Transplant .[ Google Scholar ] .Nephrol .Dial .Transplant .[ Google Scholar ] [ CrossRef ] .National Kidney Foundation .", "label": "", "metadata": {}, "score": "130.71646"}
